Cached score snapshot

US.JNJ · Johnson & Johnson

110分制 48.2/110；5D動能v2 0/50；排序分 48.2/160

Back to ranking Open volume snapshot

Ranking score 48.2/160

Main score 48.2/110

5D momentum v2 0/50

Rank #390

Setup grade F 19.9

Score breakdown

避免

Medium twelvedata

Score and price trend

F 19.9 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

**Historical projection**
Model	Median	P25/P75	歷史相似情境上漲比例	Down5	Actual / compare
Rolling DOE best · score 2.819 · anchors 120	+1.13%	-1.04% / +3.42%	63.4%	4%	Actual +4.20% · vs median +3.07% · inside 25-75 band
30D observation	+6.79%	+1.48% / +12.81%	79%	9.4%	Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160	+1.83%	-0.34% / +4.14%	70.6%	2.5%	Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-04-23 → 2026-08-31 · 351 archived points · 3 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 48.2

Display grade 避免

Model version cursor_18_27_news_v2_160

Main score 48.2/110 (避免)

5D momentum v2 0/50 (無)

Score with momentum v2 48.2/160 (低排序)

Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60

ma20 252.8465

ma50 239.143

close 248.82

prevClose 253.04

avgVolume20 8804468

volumeRatio 0.92

changePercent -1.67

Metrics snapshot

close 248.82

volume 8111650

changePercent -1.67

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 48.2/110

Main rating 避免

5D momentum v2 0/50

Score with momentum v2 48.2/160

Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.4/5 · 優秀

Dimension score 4.4/5

Dimension grade 優秀

Sub-items

pbPoints 0.2

pePoints 0.2

epsPoints 0.75

roePoints 0.75

debtPoints 0.5

marginPoints 0.6

turnoverUsdM 2018.3408

volumePoints 0.5

revenuePoints 0

dividendPoints 0.4

marketCapPoints 0.5

資金流 — 6.8/20 · 較差

Dimension score 6.8/20

Dimension grade 較差

Sub-items

cmfPoints 1.6

mfiPoints 0.8

obvPoints 1.6

vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL

symbol US.JNJ

message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.

optional true

holderCount n/a

holderPoints 2

top10ShareRatio n/a

concentrationPenalty 0

institutionPoints 2

市場環境 — 7.2/15 · 較差

Dimension score 7.2/15

Dimension grade 較差

Sub-items

vix

score 1.8

details

source twelvedata+fred

vixClose 18.77

trend

score 0.8

details

qqq

ma20 716.1175

ma50 719.011

name QQQ

close 696.06

points 0.4

spy

ma20 744.7885

ma50 744.5456

name SPY

close 742.09

points 0.4

source twelvedata+fred

atrPct 2.6131

atrPoints 3

cciPoints 1.6

vixPoints 1.8

marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20

Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model

articleCount 8

catalystCount 0

catalystPoints 2

風險管理 — 7/10 · 良好

Dimension score 7/10

Dimension grade 良好

Sub-items

position

score 1.8

details

atrPct 2.6131

turnoverUsdM 2018.3408

liquidityPoints 0.8

volatilityPoints 1

rrPoints 1.4

stopLevels

symbol US.JNJ

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 235.8164

strength_details

ma_score 1.5

atr_score 2

rsi_score 1

macd_score 1.5

volume_score 1

market_adjustment 1

risk_reward_ratio 1

stop_loss_percent 5.2

take_profit_price 261.261

target_multiplier 1.6

technical_strength 1.38

take_profit_percent 5

positionPoints 1.8

stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.2

stopLossPercent 5.2261

diversificationPoints 2

技術信號 — 16.8/30 · 較差

Dimension score 16.8/30

Dimension grade 較差

Sub-items

bbPoints 2.4

adxPoints 3

sarPoints 1.2

vcpPoints 1.5

macdPoints 2.4

vcpPayload

vcp_pass false

vcp_score 1.5

vcp_reason 跌縮量(近10日4日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N

vcp_metrics

up_days 4

vol_ref 8813293.3333

down_days 5

vcp_ready false

above_ma50 true

avg_vol_10 8147790

avg_vol_20 9348375

avg_vol_30 8813293.3333

range_pct_10 0.094

range_pct_20 0.1685

range_pct_30 0.1749

up_expand_ok true

lookback_used 59

near_20d_high false

contraction_ok false

down_shrink_ok true

up_expand_days 3

breakout_20d_ok false

vol_ratio_10_30 0.9245

dist_to_20d_high 0.0765

down_shrink_days 4

breakout_level_20d 269.43

vcp_breakout_confirm false

contraction_ratio_10_30 0.5371

vcp_name_en Volatility Contraction Pattern

vcp_name_zh 波動收縮形態

vol_contraction false

kdjAdxPoints 0.5

rsiKdjPoints 2.4

volumeWeight 2

maCrossPoints 1.6

shortRsiPoints 0

shortMacdPoints 0.4

volConfirmPoints 0.6

volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差

Dimension score 4/10

Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model

articleCount 8

negativeHits 0

positiveHits 3

sentimentScoreRaw 0.9

sentimentData

raw {"id":140963403,"url":"https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.","category":"company","datetime":1784573756,"headline":"Reading Between The Lines Of JNJ Stock's Latest Call"}, {"id":140953052,"url":"https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...","category":"company","datetime":1784477270,"headline":"Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"}, {"id":140919720,"url":"https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.","category":"company","datetime":1784205864,"headline":"Why Is The Market Punishing JNJ Stock?"}, {"id":140914232,"url":"https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.","category":"company","datetime":1784149262,"headline":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."}, {"id":140912735,"url":"https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"JNJ","summary":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...","category":"company","datetime":1784131079,"headline":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"}, {"id":140909593,"url":"https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...","category":"company","datetime":1784128337,"headline":"Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"}, {"id":140909601,"url":"https://finnhub.io/api/news?id=b5061df4902a47af987466427333da6c9fe92bdb416e459fa06f1c832924ea69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1784122204,"headline":"Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"}, {"id":140908262,"url":"https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1784115002,"headline":"Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"}

raw_source {"id":140964880,"url":"https://finnhub.io/api/news?id=12a8abdbc76bf7f5d75a741fcb8bf92b1169e627404cdd9748c5e4427653cfaf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read what's driving outlook.","category":"company","datetime":1784578140,"headline":"Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate"}, {"id":140963421,"url":"https://finnhub.io/api/news?id=6ea0dd033658292f48582a592a40caa31066d357172a543dd20d199c2861cc74","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.","category":"company","datetime":1784574905,"headline":"The Robot Maker's Paradox"}, {"id":140962978,"url":"https://finnhub.io/api/news?id=02b2e30e4b5a8015da142e1b9a1f892637cc927d311f40cc472a5668f9bca33d","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.","category":"company","datetime":1784574604,"headline":"Stay informed with the top movers within the dow jones index on Monday."}, {"id":140963403,"url":"https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.","category":"company","datetime":1784573756,"headline":"Reading Between The Lines Of JNJ Stock's Latest Call"}, {"id":140963423,"url":"https://finnhub.io/api/news?id=26047126ae59bd8c4eb72c217ec847dd194744894cd020aa98db1bbb6da3a19e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.","category":"company","datetime":1784571665,"headline":"What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?"}, {"id":140963424,"url":"https://finnhub.io/api/news?id=589a1dde19072b6d106740e598d7398a3c273b730e0ffb276308b41b42040853","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.","category":"company","datetime":1784570231,"headline":"Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD"}, {"id":140963405,"url":"https://finnhub.io/api/news?id=953f03a95ac4369d23919084ddcefbfe8771f49595f8b6d1dbc914ca7cd2fca0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.","category":"company","datetime":1784569523,"headline":"Eli Lilly Stock And The Price Of Confidence"}, {"id":140960594,"url":"https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?","category":"company","datetime":1784551980,"headline":"Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"}, {"id":140959509,"url":"https://finnhub.io/api/news?id=c8528b8311704302ec45b4ffa65ff0f68ee49d76d3993cfcb752857c60ab52b6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"LQDA, BILL and Colgate-Palmolive highlight recent Zacks picks as multiple portfolios outperformed or posted strong stock gains despite market volatility.","category":"company","datetime":1784550840,"headline":"Beat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focus"}, {"id":140959510,"url":"https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.","category":"company","datetime":1784549820,"headline":"Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."}, {"id":140958951,"url":"https://finnhub.io/api/news?id=5ed9acc8832a619e0dcafb8eca77d97a1e2404577fca62c7969d2a1bbc22ad55","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"ImmunityBio (IBRX) cautious buy: Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise riskâread now.","category":"company","datetime":1784536225,"headline":"ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)"}, {"id":140958130,"url":"https://finnhub.io/api/news?id=ec6706319150549ddafa63e0a3db84a31d57f725ac1deda3893c213e428ab5e8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.","category":"company","datetime":1784534400,"headline":"Bear of the Day: J&J Snack Foods (JJSF)"}, {"id":140957651,"url":"https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.","category":"company","datetime":1784527200,"headline":"What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."}, {"id":140955522,"url":"https://finnhub.io/api/news?id=8d88b130ffa95c1632bba1a2a2e600b109439fdb1e85c0c8ffa6f37540cd5258","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"J&J has more than 28 sources of blockbuster revenue.","category":"company","datetime":1784500200,"headline":"Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?"}, {"id":140954711,"url":"https://finnhub.io/api/news?id=bd7f9275f6da066da0e062bbc8c0c2967aae456c9c00c3c32cd0ef0849b285c8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"They can help stabilize your portfolio in these otherwise volatile times.","category":"company","datetime":1784492400,"headline":"My 2 Favorite Dividend Kings to Buy Right Now"}, {"id":140953052,"url":"https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...","category":"company","datetime":1784477270,"headline":"Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"}, {"id":140951671,"url":"https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.","category":"company","datetime":1784467858,"headline":"3 Biggest Pharma Giants: Buy, Sell or Hold?"}, {"id":140951727,"url":"https://finnhub.io/api/news?id=4ae5fefce3d887eea60615731dbad10a3cf82c75257323d81f2e4c81c3a0cde3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.","category":"company","datetime":1784466389,"headline":"Would You Rather Earn $55,000 Today or $110,000 in 20 Years?"}, {"id":140951073,"url":"https://finnhub.io/api/news?id=fafc6aeb110fdd02064f73a91ea365091609ea30e4fb379d6dcb9508affe1c6d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.","category":"company","datetime":1784458843,"headline":"From a $38,000 Income to $84,000 Without Investing Another Dollar"}, {"id":140950551,"url":"https://finnhub.io/api/news?id=f01b55cce75788117c7e394aa1e666da2acbea913eccbbe07be2af1e72923c65","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Headline inflation keeps rising faster than Social Security adjustments, quietly shrinking what retirement actually buys. A small, dedicated portfolio sleeve could fund those annual increases entirely from income, but the tier you choose changes everything about how much capital you actually need.","category":"company","datetime":1784452337,"headline":"The Portfolio That Lets You Ignore Inflation"}, {"id":140943803,"url":"https://finnhub.io/api/news?id=0dc2c819466c7138315ffa76be796026e4c9152e78e0aa2ecd3903decb24e813","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.","category":"company","datetime":1784387281,"headline":"The Portfolio That Gives You a $2,000 Raise Every Year"}, {"id":140943075,"url":"https://finnhub.io/api/news?id=967d9cb8efa721530bf134eb3b72fb54af112a8dce5b14647ab21b605e484810","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.","category":"company","datetime":1784379647,"headline":"The Portfolio That Lets You Cruise Through the News, Unbothered"}, {"id":140943050,"url":"https://finnhub.io/api/news?id=b6726c67b6d318f590ea801e8e23e38a41d664def7724f009c1732cc043834e1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.","category":"company","datetime":1784376045,"headline":"3 Dividend Stocks That Have Survived Every Market Crash in July"}, {"id":140942415,"url":"https://finnhub.io/api/news?id=c189e19fb9e0837e2ced094a748f8a447c86c96f6cd670336ac539cab7f21005","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Lifelong learning sounds like a noble habit until you price it out across decades and realize it behaves more like a recurring expense than a one-time splurge. The portfolio that funds it may look nothing like the obvious choice.","category":"company","datetime":1784373097,"headline":"Here’s the Funding It Takes to Keep Learning Forever"}, {"id":140951072,"url":"https://finnhub.io/api/news?id=73534d700060689b3f3e12bb0a8fd766db23bf8c5f3b1546e2cec50941fb3bf1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.","category":"company","datetime":1784372400,"headline":"MarketBeat Week in Review – 07/13- 07/17"}, {"id":140939403,"url":"https://finnhub.io/api/news?id=57d40fe7bb5c8aac6f79be0256a9f813474876b809b4a24f9b6e6987567d036e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.","category":"company","datetime":1784333456,"headline":"If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income"}, {"id":140939163,"url":"https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.","category":"company","datetime":1784328964,"headline":"Abbott Just Showed Its Growth Engine Has More Than One Cylinder"}, {"id":140939161,"url":"https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.","category":"company","datetime":1784325063,"headline":"The Real Question Buried Inside Merck Stock's Premium Price"}, {"id":140937906,"url":"https://finnhub.io/api/news?id=a0e0cf5d5229803aafd81bc10762576800986410f1c10defc757f88a1be078dd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Jim Cramer named five blue-chip stocks the market punished after strong earnings, and he's betting that millions of investors and billions of dollars got it completely wrong.","category":"company","datetime":1784322864,"headline":"Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks"}, {"id":140937907,"url":"https://finnhub.io/api/news?id=544c9a5b6ab515dd6fe654dd847834a8214c9a346b18b078ca02fbcb4330a814","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.","category":"company","datetime":1784322800,"headline":"Jim Cramer Says Oracle Is “Going Down” and Avoid Every Liquor Stock. Here’s What He’d Buy Instead"}, {"id":140936306,"url":"https://finnhub.io/api/news?id=9379fd9a229dde89bca8d1d8f41d09e6f5b887ee5f712f95edadbe7a94d281c2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.","category":"company","datetime":1784315450,"headline":"DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch"}, {"id":140935746,"url":"https://finnhub.io/api/news?id=b8d366b0978045461c3e2f0f805013981ee50b4718778eb2469f0e71bb1d2514","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1784315404,"headline":"These dow jones stocks are moving in today's session"}, {"id":140934459,"url":"https://finnhub.io/api/news?id=a2ee62a66c63a946d94c3e6beb499c40b3125181a2923f5fa2fc732d6e9e4955","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.","category":"company","datetime":1784307459,"headline":"VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way"}, {"id":140933705,"url":"https://finnhub.io/api/news?id=cf957e631b08afbc352ac0c9645261668019b12720ed7857cae855b3ae4f2250","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1784306404,"headline":"Top dow jones movers in Friday's session"}, {"id":140933340,"url":"https://finnhub.io/api/news?id=dc6646e28e14b3fdaff43894e8f7f8bbb22af0391c056fc946d02d9e5a21b04b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.","category":"company","datetime":1784304654,"headline":"SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution"}, {"id":140932972,"url":"https://finnhub.io/api/news?id=88bacf0e7e75d7ad7490cf737b97af9956511d5def5cdbef0d549d91e59d52d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?","category":"company","datetime":1784302670,"headline":"Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?"}, {"id":140932973,"url":"https://finnhub.io/api/news?id=0504e442cf7f265bb43b0e44d54c0386af3ed0aa7fd4f592d362e90177bbdfa3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.","category":"company","datetime":1784298660,"headline":"J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why"}, {"id":140931435,"url":"https://finnhub.io/api/news?id=43bdff8a716708433fb4dc9ca77c1f32465999080349e9d6bee352b6884763f2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.","category":"company","datetime":1784295671,"headline":"Stock Market Today: Nasdaq Leads Indexes Down; SpaceX Slides As Flight Canceled (Live Coverage)"}, {"id":140931563,"url":"https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.","category":"company","datetime":1784290654,"headline":"Can Abbott Stock Deliver on Its Second-Half Growth Promise?"}, {"id":140931564,"url":"https://finnhub.io/api/news?id=c1f3439f3f31bb5e63491154cf43bcb3dc1f5d6f47086643b3ecba50b2f29e50","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.","category":"company","datetime":1784289180,"headline":"Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years"}, {"id":140930733,"url":"https://finnhub.io/api/news?id=2f16834b08c6c17f3fe26ebf1ea738c1f438efeb6aa48d5eb4eb3ba6a91c9cde","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A portfolio that pays $27,000 a year in dividends sounds modest. Left alone for a little more than a decade of steady dividend growth, that same income stream can quietly grow toward $66,000 without a single additional dollar of savings. That is the basic appeal of dividend growth investing: the arithmetic of today’s yield matters, ... Growing an Income Tree: From $27,000 to $66,000","category":"company","datetime":1784286034,"headline":"Growing an Income Tree: From $27,000 to $66,000"}, {"id":140934862,"url":"https://finnhub.io/api/news?id=9254cbc0007632f41e4f18a578ee59d8ca248cce6c424d6e754fd2559e0baa3e","image":"","source":"Benzinga","related":"JNJ","summary":"Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.","category":"company","datetime":1784277291,"headline":"Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target"}, {"id":140926081,"url":"https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.","category":"company","datetime":1784236020,"headline":"Why Healthcare Stocks Look Like a Haven in This Market"}, {"id":140934035,"url":"https://finnhub.io/api/news?id=582214e1504528124d4be9c4af6af3802955bcbb5b2ad89b6f8829dfea0ac010","image":"https://image.cnbcfm.com/api/v1/image/108336317-5ED3-MM-A-BLOCK-071626.jpg?v=1784242037&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"'Mad Money' host Jim Cramer talks going against the grain in the market.","category":"company","datetime":1784231304,"headline":"Jim Cramer: It takes a lot of guts to disagree with the market about a stock after it reports"}, {"id":140924324,"url":"https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.","category":"company","datetime":1784224421,"headline":"Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"}, {"id":140922631,"url":"https://finnhub.io/api/news?id=7b429b088d655c237aac8342e677ff2e6a0d4bbbe45d0f80f410066bf2a7a864","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those ... The Portfolio That Pays All Your Car Repairs For Life","category":"company","datetime":1784224058,"headline":"The Portfolio That Pays All Your Car Repairs For Life"}, {"id":140924331,"url":"https://finnhub.io/api/news?id=2cccc71304a92dbf83c35d1711fa335b36545f9818f085bb547e2a190d5858bd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.","category":"company","datetime":1784222460,"headline":"Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?"}, {"id":140922632,"url":"https://finnhub.io/api/news?id=7c29be2f94767e0c8e1e1ad8878c710d0617b7fa7550c65b0b37d527287ef6d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.","category":"company","datetime":1784218260,"headline":"Sector ETFs to Win on Q2 Earnings Growth Potential"}, {"id":140924212,"url":"https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Johnson & Johnsonâs strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.","category":"company","datetime":1784217215,"headline":"I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"}, {"id":140920971,"url":"https://finnhub.io/api/news?id=6eac034c6914e1faa4d3597b25972ecf5df2fdb6a0f3aad2a0291a50be75e185","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.","category":"company","datetime":1784216700,"headline":"Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion"}, {"id":140920972,"url":"https://finnhub.io/api/news?id=599fd74550f7b98d365d009af33a716949e9a10cb0c48e26cf5ef5e8637d71f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson's (JNJ) Innovative Medicine segment momentum is building into 2027, with the compa","category":"company","datetime":1784215796,"headline":"Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says"}, {"id":140920973,"url":"https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.","category":"company","datetime":1784212620,"headline":"Why Abbott Stock Is Having Its Best Day in 24 Years"}, {"id":140925253,"url":"https://finnhub.io/api/news?id=7b55a75cfcff35bfaea03818a622a465035efd6daf3d0186d0f34f068e6f793e","image":"","source":"Benzinga","related":"JNJ","summary":"Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $258 to $265.","category":"company","datetime":1784211124,"headline":"Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265"}, {"id":140920962,"url":"https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.","category":"company","datetime":1784210761,"headline":"Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"}, {"id":140920975,"url":"https://finnhub.io/api/news?id=7c8ef675a3c6fa5fb020f15ac8b4d391cda0c47a701fbe8e4984298f9b1e9e13","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.","category":"company","datetime":1784210400,"headline":"Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat"}, {"id":140920976,"url":"https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.","category":"company","datetime":1784210345,"headline":"Why Abbott Stock Is Reimagining Its Future"}, {"id":140923118,"url":"https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103","image":"https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.","category":"company","datetime":1784208257,"headline":"UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"}, {"id":140919686,"url":"https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.","category":"company","datetime":1784207994,"headline":"What Could Push LLY Stock Higher From Here?"}, {"id":140919685,"url":"https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.","category":"company","datetime":1784207994,"headline":"The Real Engine Behind Johnson & Johnson Stock's Next Climb"}, {"id":140919720,"url":"https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.","category":"company","datetime":1784205864,"headline":"Why Is The Market Punishing JNJ Stock?"}, {"id":140925255,"url":"https://finnhub.io/api/news?id=a1e7a18b2666f804b907fee1ef3b62977722ec84865ee61dc95830e221a48894","image":"https://cdn.benzinga.com/files/images/story/2026/07/16/Johnson--Johnson.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"The reasons why RBC Capital Markets maintains its stock rating.","category":"company","datetime":1784203897,"headline":"Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst"}, {"id":140919721,"url":"https://finnhub.io/api/news?id=6520635232f64f8347ba4e9dff3721065414e7b36bcf1950f94d2c6548cdc023","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"NEW BRUNSWICK, N.J., July 16, 2026--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all.","category":"company","datetime":1784203860,"headline":"Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award"}, {"id":140919722,"url":"https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.","category":"company","datetime":1784203500,"headline":"Why Abbott Earnings Are Sending the Stock Higher"}, {"id":140919723,"url":"https://finnhub.io/api/news?id=de8e48f037f5c09136d811016bc9ddf198f5b74d438512b6dacad9fa099e2580","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"RAYNHAM, Mass., July 16, 2026--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.","category":"company","datetime":1784203200,"headline":"DePuy Synthes Acquires Expanding Innovations™"}, {"id":140925256,"url":"https://finnhub.io/api/news?id=f6de372db2648d397e31f9942e51ccb26c3dd7374c1db33b16261b2fe74c1950","image":"","source":"Benzinga","related":"JNJ","summary":"RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $287 price target.","category":"company","datetime":1784199879,"headline":"RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $287 Price Target"}, {"id":140925257,"url":"https://finnhub.io/api/news?id=c4ad69c879606e9a3f256389df43bbfaf5fa9660a189217a14842a88cab536dc","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"A report on July 15, 2026 shows that Representative Thomas Kean from New Jersey sale stock in Alphabet (NASDAQ:GOOGL), valued between $26,012 and $215,000. According to the July filing, the transaction occurred on June","category":"company","datetime":1784199622,"headline":"New Jersey Rep. Thomas Kean Sold Over $26K Worth of Alphabet Stock: Here’s What You Should Know"}, {"id":140925258,"url":"https://finnhub.io/api/news?id=8bf525878cd1213d29b7dccd45b7fb5e3eb5eb5f9f5d242f48df0f4e450f5507","image":"","source":"Benzinga","related":"JNJ","summary":"Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $263 to $272.","category":"company","datetime":1784199227,"headline":"Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272"}, {"id":140918830,"url":"https://finnhub.io/api/news?id=b8067d2e125f2fadd902082d475fcb21d24467c27a57848a9d67cfeb5786361c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income","category":"company","datetime":1784197760,"headline":"The Portfolio Blueprint for Building $20,000 a Month in Dividend Income"}, {"id":140922157,"url":"https://finnhub.io/api/news?id=386c0b9c1c3d9557d90a82f0a6e027a81e4638d8b6d3f8ba2779826e7a8c42f5","image":"https://image.cnbcfm.com/api/v1/image/108335965-17842089721784208970-47198742640-1080pnbcnews.jpg?v=1784208971&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"CNBC’s Jim Cramer delivers his daily Mad Dash.","category":"company","datetime":1784194960,"headline":"Cramer’s Mad Dash: Johnson & Johnson"}, {"id":140925259,"url":"https://finnhub.io/api/news?id=8e8ff9972320acf9872e5c5f441d391a77a1bf0345ca3e918d5ba001518be010","image":"","source":"Benzinga","related":"JNJ","summary":"Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $284 to $294.","category":"company","datetime":1784193945,"headline":"Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294"}, {"id":140925260,"url":"https://finnhub.io/api/news?id=014de1ad8e4e545a4a3f02e2d375594a5f01a2ee6dea5eaa486ec601be65e351","image":"","source":"Benzinga","related":"JNJ","summary":"The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.Expanding Innovations (EI) is a commercial-stage medical technology company","category":"company","datetime":1784189685,"headline":"Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed"}, {"id":140918128,"url":"https://finnhub.io/api/news?id=f1402859602ca724ecf65893e4e4f5820ae506617dde2d10a6da383be625d1ad","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.","category":"company","datetime":1784185971,"headline":"SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot"}, {"id":140916511,"url":"https://finnhub.io/api/news?id=e300002b4f43068403e89c192b53b22aa9c3919d052a002385f9017f92ad7e63","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Investors didn't seem to think so after the company published it.","category":"company","datetime":1784173167,"headline":"Is Johnson & Johnson a Buy After Its Latest Earnings Report?"}, {"id":140925261,"url":"https://finnhub.io/api/news?id=9f5bb9cd16e73156160575776209683ad183e46e25dbce73d4396b83af3a0168","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to","category":"company","datetime":1784166947,"headline":"Full Transcript: Johnson & Johnson Q2 2026 Earnings Call"}, {"id":140915424,"url":"https://finnhub.io/api/news?id=ab8372ecfee687d7abf018b7dce66c686ad6cd08febf8c3946af69c275a4cd45","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.","category":"company","datetime":1784150433,"headline":"Best Dividend Stocks to Buy for Dependable Dividend Growth"}, {"id":140914231,"url":"https://finnhub.io/api/news?id=f0632b36b806d3d0cb47d42432e310a59cbd17a7770bb0e0c19a70aac93b683c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.","category":"company","datetime":1784150173,"headline":"Stock Market Today, July 15: Markets Rise on Cooler Inflation and Strong Earnings Start"}, {"id":140914232,"url":"https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.","category":"company","datetime":1784149262,"headline":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."}, {"id":140912812,"url":"https://finnhub.io/api/news?id=d1dbf1f7ea79f9594822717b2881011dd0b4feefcaa01d1669fa51610f4a8da0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...","category":"company","datetime":1784144040,"headline":"Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies"}, {"id":140912443,"url":"https://finnhub.io/api/news?id=6750508196e401c3e7147c7d16e101bbbf6a7f4a57e20206b50542adf6290ea5","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.","category":"company","datetime":1784142603,"headline":"What's going on in today's session: dow jones movers"}, {"id":140912813,"url":"https://finnhub.io/api/news?id=af3b9436f23bb6328aa43e6b3e1faf8d7dd198364bfa6e28cf7cd911df9289f9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.","category":"company","datetime":1784140381,"headline":"The Open Questions On ISRG Stock"}, {"id":140911280,"url":"https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State","category":"company","datetime":1784137282,"headline":"Sector Update: Healthcare Stocks Advance in Afternoon Trading"}, {"id":140911186,"url":"https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.","category":"company","datetime":1784136544,"headline":"Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"}, {"id":140911295,"url":"https://finnhub.io/api/news?id=4a791776ab37db358676e8be6b305d1ec3123f5214f8c1346ecc26403cfddb47","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"PayPal stock leads the S&P 500 while Sandisk is among the worst performers. Micron falls as chip stocks book significant losses.","category":"company","datetime":1784134800,"headline":"Micron, PayPal, IBM, SpaceX, BlackRock, and More Stocks That Explain Today’s Market"}, {"id":140911296,"url":"https://finnhub.io/api/news?id=aee602b293e01bdae62f2d6674938ab67845e74bf45b3536a1bd3aa55fdad064","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.","category":"company","datetime":1784134793,"headline":"J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others"}, {"id":140910530,"url":"https://finnhub.io/api/news?id=d3f52428a05de534ed0291c48948492f6aadc30b433f1701d5322f7b8d1fb595","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1784133603,"headline":"Stay informed with the top movers within the dow jones index on Wednesday."}, {"id":140911297,"url":"https://finnhub.io/api/news?id=787e4c2e5b8b34dbaa7ba190f36e70608d9c07c20239be6b5eb232e1e3172fd9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.","category":"company","datetime":1784132843,"headline":"Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King"}, {"id":140912735,"url":"https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"JNJ","summary":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...","category":"company","datetime":1784131079,"headline":"Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"}, {"id":140909590,"url":"https://finnhub.io/api/news?id=88fcc255731ec69886d1295814f3e784ca3de4fa2badc7f414c8666b92de4cbb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led","category":"company","datetime":1784130649,"headline":"Top Midday Stories: PayPal Reportedly Gets Acquisition Offer From Stripe, Advent; ASML Misses Q2 EPS, Sales Estimates, Lifts Outlook"}, {"id":140909591,"url":"https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson’s second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed. J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”","category":"company","datetime":1784128500,"headline":"Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"}, {"id":140909592,"url":"https://finnhub.io/api/news?id=007d15c9cf8e2ff35d41bbed5ecbb0afd386fd8bd943e6f92ab6307e2cfd496b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.","category":"company","datetime":1784128454,"headline":"J&J raises FY26 outlook following positive Q2"}, {"id":140909593,"url":"https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...","category":"company","datetime":1784128337,"headline":"Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"}, {"id":140911298,"url":"https://finnhub.io/api/news?id=68daeb1521e8e1d59a5f8a5092dccf50dc34cd5e70838a036646bc5876a08361","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Producer Inflation Cools in June","category":"company","datetime":1784127300,"headline":"Producer Inflation Cools in June"}, {"id":140909594,"url":"https://finnhub.io/api/news?id=ec340f83e790a33d8578eaabbe70e16e33fdc6e6b4e59590d771d0a8d3a886df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.","category":"company","datetime":1784127000,"headline":"J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised"}, {"id":140909595,"url":"https://finnhub.io/api/news?id=734ecd32e0b0bb076cabb9c846905c77fbf49fb3332c67befbe8f37a58387e50","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?","category":"company","datetime":1784126640,"headline":"Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"}, {"id":140909596,"url":"https://finnhub.io/api/news?id=ccd29988ec70f94492a68a9bfcc87fe887cf810dd56988d4d935a873da283740","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...","category":"company","datetime":1784126520,"headline":"Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance"}, {"id":140909597,"url":"https://finnhub.io/api/news?id=d56e980eea938f5552ae174918377651845cf671b35640abd87fa2e22973148a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.","category":"company","datetime":1784125920,"headline":"PPI Slides in June on Lower Oil Prices, Q2 Results Continue"}, {"id":140909598,"url":"https://finnhub.io/api/news?id=7dab795452149bd3414880bc74c107b79159251545e9f97ed6871bfed9ab6e77","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"FEATURE Stocks were rising Wednesday, building on recent gains, as a cooler-than-expected producer price index print boosted investor sentiment. Wall Street also assessed another batch of quarterly earnings reports with chip-machine supplier ASML offering an encouraging read on the artificial-intelligence trade.","category":"company","datetime":1784125260,"headline":"Intel, Marvell, PayPal, IBM, and More Stocks That Explain Today’s Market"}, {"id":140909599,"url":"https://finnhub.io/api/news?id=02bc3408b143d0b0d2c85943c9e5093fa90ca7d4d087bd71c3ae77d3510fbd3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.","category":"company","datetime":1784124278,"headline":"Johnson & Johnson Q2 Earnings Call Highlights"}, {"id":140909600,"url":"https://finnhub.io/api/news?id=1d6738c6d9a78ffd93f1b782aa95276bb3cb97c56d5097551f9eecc53a118792","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.","category":"company","datetime":1784124027,"headline":"Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner"}, {"id":140908252,"url":"https://finnhub.io/api/news?id=e4f75f3b4d5bc9653feb149741bd86881e2f09000474bc9c816c18cdfe4b02f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect","category":"company","datetime":1784123441,"headline":"Johnson & Johnson Lifts Full-Year Outlook Following Second-Quarter Beat"}, {"id":140908253,"url":"https://finnhub.io/api/news?id=f8e971a5a6caad75bc55b5177e35e9617e2d8fa27564a81e9ef8f0b6a46646a1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]","category":"company","datetime":1784123188,"headline":"Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment"}, {"id":140909601,"url":"https://finnhub.io/api/news?id=b5061df4902a47af987466427333da6c9fe92bdb416e459fa06f1c832924ea69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1784122204,"headline":"Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"}, {"id":140908133,"url":"https://finnhub.io/api/news?id=480ecd1efdac3a227829eb7883cc5a86f40c88e0b34b3e5bcfe8c909920a0c06","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"(Updates with economic data, recent oil price movement, world markets' overview and corporate stock","category":"company","datetime":1784120409,"headline":"Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"}, {"id":140908255,"url":"https://finnhub.io/api/news?id=cc258d3da9ae53838311586792668a5eb94f9b6a67e133c42920618179502504","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.","category":"company","datetime":1784119721,"headline":"Healthcare Bellwether J&J Beats And Raises, But Shares Dip"}, {"id":140910451,"url":"https://finnhub.io/api/news?id=8adf3a174d992a7822510053eb8715506de936528378933346c11d59ad88c317","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1159967002/image_1159967002.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Tech analyst Dan Ives, known for his bullish calls on stocks like Apple (AAPL) and AI names announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank.","category":"company","datetime":1784118720,"headline":"Wall Street Lunch: Dan Ives Teams Up With Yorkville Securities To Launch Merchant Bank"}, {"id":140908256,"url":"https://finnhub.io/api/news?id=96eb4c84d427590062d9d4cf07c341c0c76f5da3bf6ed65246a738b27ba4dff8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"News of the day for July 15, 2026","category":"company","datetime":1784117187,"headline":"5 Things to Know Before the Stock Market Opens on Wednesday"}, {"id":140908257,"url":"https://finnhub.io/api/news?id=dffcbd487144d4902ca503dee639eaaf4fee28eafeab18706d3f53e33252bd4f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"US equity futures were edging higher pre-bell Wednesday as traders considered the latest inflation d","category":"company","datetime":1784117178,"headline":"US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"}, {"id":140908248,"url":"https://finnhub.io/api/news?id=edd8af44fdbc11a7818dc1e61ec4669942ac8cd0ad4a1001892de1ac2f9b1a85","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.","category":"company","datetime":1784117108,"headline":"Dow Jones Futures: Techs Rise, Oil Hits $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"}, {"id":140908259,"url":"https://finnhub.io/api/news?id=4bd6543c66cee9ca607ffacfe474a01c59fd8ff61427054401f77309c9bfbbee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year","category":"company","datetime":1784116945,"headline":"The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year"}, {"id":140908260,"url":"https://finnhub.io/api/news?id=25d2f4579b69c5e41cd7ab96a5efc1ac5cbc9866e68f0703118c2c0ea471ad90","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint","category":"company","datetime":1784116917,"headline":"Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength"}, {"id":140907340,"url":"https://finnhub.io/api/news?id=a4991ce4f683f91b710365cca22adbf8237f8b0e8a06f4416b51ca7ee2a6bae8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.","category":"company","datetime":1784115687,"headline":"Dow Jones Futures: Oil Prices Hit $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"}, {"id":140908261,"url":"https://finnhub.io/api/news?id=2a1b2e7c2e336f9a72b568b5ac722ab04c6ed98c7f6cdafa9f706f35418c5d37","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.","category":"company","datetime":1784115480,"headline":"Why Johnson & Johnson Stock Is Falling Even After a Guidance Hike"}, {"id":140909365,"url":"https://finnhub.io/api/news?id=76a3181bef3b2c7150e33ad598c8a16d2c5b4eb03982ca724028760ddb0d572e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266159678/image_2266159678.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Johnson & Johnson Q2 2026 results: 6.6% revenue growth, Pharma/MedTech strength, and dividend stability. Click for this JNJ earnings update.","category":"company","datetime":1784115253,"headline":"Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street"}, {"id":140908262,"url":"https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1784115002,"headline":"Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"}, {"id":140907559,"url":"https://finnhub.io/api/news?id=1fcb7f84b47d3bc10563f5ccefe5eebb163514c3e049267d25c046760da9f4a1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.","category":"company","datetime":1784114820,"headline":"Intel, Johnson & Johnson, ASML, and More Stocks That Explain Today’s Market"}, {"id":140907215,"url":"https://finnhub.io/api/news?id=572fb61f26bb74b899035732346e05f98565a6037204b53e0381a10ee1e45214","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp","source":"ChartMill","related":"JNJ","summary":"J&J reported Q2 earnings in line with estimates, raised full-year guidance for sales and EPS, yet saw muted market reaction with stock down ~1.9% pre-market.","category":"company","datetime":1784114488,"headline":"Johnson & Johnson (NYSE:JNJ) Raises Full-Year Guidance After In-Line Q2 Results"}, {"id":140907439,"url":"https://finnhub.io/api/news?id=76dbabe7c9bad302caf7f990b149c1d0f961308d4c92e74ca73b24759b95cb82","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.","category":"company","datetime":1784114094,"headline":"Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)"}, {"id":140907440,"url":"https://finnhub.io/api/news?id=d4fc0e49f6e84d53b084291f70ad0fbf1c7a69ea8a5e79f1be0d2c5663bcdcba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.","category":"company","datetime":1784113435,"headline":"Johnson & Johnson beats estimates but shares dip"}, {"id":140907441,"url":"https://finnhub.io/api/news?id=ba0258ea77d7da09c8ab76bbdbc2029b8a4ec44098d830ba03fc4e837e4aab91","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson will release its second-quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus...","category":"company","datetime":1784112366,"headline":"How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings"}, {"id":140907442,"url":"https://finnhub.io/api/news?id=d1efded5187965b2a59a2176420140c6e70982a359b4b270f05f5ecdfea4f944","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026.","category":"company","datetime":1784111100,"headline":"Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026"}, {"id":140907443,"url":"https://finnhub.io/api/news?id=c49fb7ab1c6a5837fa280079290342e09b697867de272310a858fd2028764223","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor","category":"company","datetime":1784110920,"headline":"Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026"}, {"id":140907444,"url":"https://finnhub.io/api/news?id=4f08eae507e1193ecb087dcc13a87d4db5cffa3d7fa6b20ed072017e691b054f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. \"Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,\" said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. \"With raised guidance and quarterly sales surpassin","category":"company","datetime":1784110800,"headline":"Johnson & Johnson reports Q2 2026 results, raises 2026 outlook"}, {"id":140907445,"url":"https://finnhub.io/api/news?id=845f41dc98196ae4fdb92ce50ceddd355048dd46df86616dbd3b41d7db42e9cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Eight thousand dollars a month is the kind of retirement income target that looks simple until the yield math starts moving underneath it. It translates to $96,000 a year, but the portfolio needed to produce that income can vary by well over $1 million depending on whether the investor accepts a 3.5% yield, a 6% ... What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield","category":"company","datetime":1784110629,"headline":"What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield"}, {"id":140907446,"url":"https://finnhub.io/api/news?id=2d02d5cf0d75ca0cae255786ac3585d494c1f5d01af68e5d8c01eab28b11bce2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data. Nasdaq 100 futures added 0.4%. Dow Jones Industrial Average futures rose 81 points, or 0.2%.","category":"company","datetime":1784110182,"headline":"Stock Futures Jump. Market Rally Gathers Pace as Earnings Season Ramps Up."}, {"id":140911822,"url":"https://finnhub.io/api/news?id=fa17715f1b72478afab6a288d6534679bb604cbc46e9c70eb3af7c4aabfe45b6","image":"https://cdn.benzinga.com/files/images/story/2026/07/15/Johnson--Johnson.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.","category":"company","datetime":1784107911,"headline":"Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook"}, {"id":140910786,"url":"https://finnhub.io/api/news?id=c4a2d146e21fb7daa47e67c402fb3a6be0643ebcff00aa0e2b61cce8bc1a91ef","image":"https://image.cnbcfm.com/api/v1/image/108260658-17701229642026-02-03t122144z_241610661_rc2bejauv8r4_rtrmadp_0_paypal-results.jpeg?v=1770122981&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"These are the stocks posting the largest moves premarket.","category":"company","datetime":1784100829,"headline":"Stocks making the biggest moves premarket: BlackRock, PayPal, ASML, Morgan Stanley & more"}, {"id":140910787,"url":"https://finnhub.io/api/news?id=0a6f3fe8f6935b5badfdfb4b9e31644dc77a38f0ee71f38c650e4c414cc302f2","image":"https://image.cnbcfm.com/api/v1/image/108335230-4ED1-MC-071526-Vamil.jpg?v=1784114956&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"Vamil Divan, Senior Biopharma Research Analyst at Guggenheim Securities, said Johnson & Johnson has moved past patent losses and is benefiting from a strong pipeline of new products driving future growth.","category":"company","datetime":1784100565,"headline":"Vamil Divan: We are looking for accelerating growth into 2027"}, {"id":140908853,"url":"https://finnhub.io/api/news?id=89e4833a9fa20ccd77cb554da88c61423a07541323a70d40a9fcab10af32f087","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Companies Reporting Before The Bell\n• VCI Global (NASDAQ:VCIG) is estimated to report earnings for its Fiscal Year 2025. \n• PNC Financial Services Gr (NYSE:PNC) is projected to report quarterly earnings at $4.43 per","category":"company","datetime":1784099470,"headline":"Earnings Scheduled For July 15, 2026"}, {"id":140911824,"url":"https://finnhub.io/api/news?id=11a8881829fa4914e6ee2fc5098e938c170e5ed482291fd038de8dbfa2c660f6","image":"","source":"Benzinga","related":"JNJ","summary":" Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the","category":"company","datetime":1784096758,"headline":"Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoY"}, {"id":140911825,"url":"https://finnhub.io/api/news?id=03d694a3a8b38f252ce1e205d13eeb0463233f273a356f676bb5de03344a8c5b","image":"","source":"Benzinga","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 analyst estimate. Raises FY2026 sales outlook from $100.300 billion-$101.300 billion to $100.800","category":"company","datetime":1784096536,"headline":"Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est"}, {"id":140911826,"url":"https://finnhub.io/api/news?id=7ba5559f31c8d34a08ffe13e149cac885181af43fa70368300ee8346b21d1074","image":"","source":"Benzinga","related":"JNJ","summary":"]","category":"company","datetime":1784096449,"headline":"Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate"}, {"id":140908855,"url":"https://finnhub.io/api/news?id=0bd9ec8d7935ec4e27c1dc576e933c71816c604d8f0f286f1acb887ea775203b","image":"https://cdn.benzinga.com/files/images/story/2026/07/15/People-Silhouettes-On-American-Stock-Mar.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"July 15, 2026: Polymarket traders expect the S&P 500 to open higher on Wednesday after cooler inflation sharply reduced July Fed hike expectations.","category":"company","datetime":1784089520,"headline":"Stock Market: Will S&P 500 Open Up or Down Today?"}, {"id":140910605,"url":"https://finnhub.io/api/news?id=cc8b2768dae29ccd6206162d2aecd5c2e53559f0e95747d25b043050577d0301","image":"https://cdn.benzinga.com/files/images/story/2026/07/15/Fear-and-Greed.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"CNN Money Fear and Greed index improved, but remained in Fear zone. U.S. stocks mostly higher on inflation data.","category":"company","datetime":1784085469,"headline":"Nasdaq Gains Over 200 Points Following Inflation Report: Investor Sentiment Improves, Greed Index Remains In ‘Fear' Zone"}, {"id":140910606,"url":"https://finnhub.io/api/news?id=7931fb5218a4714b2f3aead3ebddba4767322b6b545a5af35cbc89c7d60d1f5a","image":"https://cdn.benzinga.com/files/images/story/2026/07/15/London--United-Kingdom---February-26--20.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Morgan Stanley, Pentair, Johnson & Johnson expected to release earnings, ASML posts strong results, Progressive to report","category":"company","datetime":1784082564,"headline":"Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday"}, {"id":140904169,"url":"https://finnhub.io/api/news?id=767d2ade90ef611607c1a4bca821949c13486a341ca98a855029fee95d289c7e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.","category":"company","datetime":1784072870,"headline":"Dow Jones Futures Rise; Goldman, CrowdStrike Jump, But AI Stocks Need To Do This"}, {"id":140902827,"url":"https://finnhub.io/api/news?id=1f6b453f31d34dccef7a765a871c263304660a1877335a34668902c89bd77538","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.","category":"company","datetime":1784062760,"headline":"Dow Jones Futures: Goldman, CrowdStrike Jump, AI Stocks Need To Do This; ASML, Morgan Stanley Due"}, {"id":140910779,"url":"https://finnhub.io/api/news?id=e36c920525aaa0874fb55e565da7f7840590e65eeb85912374ef661a4127c708","image":"https://image.cnbcfm.com/api/v1/image/108324283-17818184352026-06-18t212644z_311932191_rc2kwlaz3beo_rtrmadp_0_usa-stocks.jpeg?v=1781818551&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"Stocks closed higher on Tuesday, helped by signs of easing inflation, which boosted investor hopes that the Federal Reserve can hold off on rate hikes for the moment.","category":"company","datetime":1784056328,"headline":"Wednesday's big stock stories: What’s likely to move the market in the next trading session"}, {"id":140901110,"url":"https://finnhub.io/api/news?id=a418695849289d29baabb02fccad0cc1323fa81f759a05f46d8ec554e1e50864","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.","category":"company","datetime":1784056204,"headline":"Top dow jones movers in Tuesday's session"}, {"id":140901466,"url":"https://finnhub.io/api/news?id=3b28393a5831026f9ac3732237381ea888082eee864a93bb498cf961a423a22f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.","category":"company","datetime":1784052407,"headline":"The Paid-To-Hold Play On ISRG Stock: A 12% Income"}, {"id":140901439,"url":"https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.","category":"company","datetime":1784051674,"headline":"What Lilly's Peer-Beating Numbers Cost You"}, {"id":140902248,"url":"https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.","category":"company","datetime":1784047680,"headline":"A Fresh Look At Syndax Pharmaceuticals"}, {"id":140899749,"url":"https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.","category":"company","datetime":1784046620,"headline":"This Healthcare Giant Still Checks Every Box for Long-Term Investors"}, {"id":140902323,"url":"https://finnhub.io/api/news?id=328fd13fc461312f4abaa2aa4d14fd146e994b9dd8b50474f58fe81e55a60d67","image":"https://cdn.benzinga.com/files/images/story/2026/07/14/Marketplace-Enrollment-Declines.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Earnings for ASML, Progressive, and BNY Mellon are coming with implied moves of 3.89%, 3.89%, and 4.14% respectively, reflecting market expectations for post-print repricing risk.","category":"company","datetime":1784046094,"headline":"ASML Could Swing 7.5% After Earnings on Wednesday"}, {"id":140899750,"url":"https://finnhub.io/api/news?id=804eb2632a3ad3085591338bd6e8d9f028e77cc907f15421b301c5d84b07d50e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A $1.4 million nest egg is far above the typical U.S. retirement account balance, but the check it writes each month depends entirely on how the assets are arranged. At a 3.5% yield, the portfolio produces $49,000 a year. At a 10% yield, it produces $140,000. The difference looks simple on a spreadsheet, but it ... A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets","category":"company","datetime":1784045547,"headline":"A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets"}, {"id":140898040,"url":"https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.","category":"company","datetime":1784043119,"headline":"HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"}, {"id":140898076,"url":"https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.","category":"company","datetime":1784039400,"headline":"Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"}, {"id":140898077,"url":"https://finnhub.io/api/news?id=bfd8f460c4d367b16145d1b4ffd79af32bdd28c9d051cfdbb4030e02693a8e59","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson stock has returned 77.8% over the past five years and now sits at a point where a Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside while the broader valuation checks look much less generous. A 77.8% five year return sets the context for assessing whether today’s price still leaves enough potential reward for the risk involved. Progress in oncology and autoimmune drugs can support long term cash flow expectations, while ongoing talc related...","category":"company","datetime":1784038477,"headline":"Johnson & Johnson (JNJ) Stock May Be Reasonable After Talc Verdict Ruling"}, {"id":140898078,"url":"https://finnhub.io/api/news?id=662432f9abe149819b5e3060f6fa533bf33f671aa0c5610830a23d64bd69986f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"San Francisco makes passive income math unforgiving. SmartAsset’s 2026 comfort-salary study estimates that a single adult needs about $134,950 in pretax income to live comfortably in the city, among the highest figures in the country. Turning that paycheck into dividend income is not just a yield exercise. The yield an investor reaches for changes both ... A Dividend Portfolio That Can Cover the Cost of Living in San Francisco","category":"company","datetime":1784037813,"headline":"A Dividend Portfolio That Can Cover the Cost of Living in San Francisco"}, {"id":140898041,"url":"https://finnhub.io/api/news?id=f81b5704db160b35b4aa4e9fe38b791120b54b59fe0684be4ae1b6f05f59f94e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.","category":"company","datetime":1784037240,"headline":"Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge"}, {"id":140896860,"url":"https://finnhub.io/api/news?id=69cac81872a917b82ac0a4526f38f4b08928a2ae81ab419989126f3ac804ca95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.","category":"company","datetime":1784033543,"headline":"ISRG Stock: What Does Its Valuation Imply?"}, {"id":140896861,"url":"https://finnhub.io/api/news?id=50ca3d5ebf3ad6a5d9c62186736be99edd52483da4c3f0093b6e6925bb8eca50","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A series of big bank results kicked off the second quarter earnings season on Tuesday.","category":"company","datetime":1784030838,"headline":"Earnings live: Wall Street bank stocks mixed despite profit haul"}, {"id":140899751,"url":"https://finnhub.io/api/news?id=d1aa5a730c62073f57143bd0a22d3a9540c6140220402a1e4e9ae24f822d7381","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.","category":"company","datetime":1784030400,"headline":"Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill"}, {"id":140903560,"url":"https://finnhub.io/api/news?id=4de721486aee9a85d315832d79e4a7091464b812938b3bfd4f046dad27e0b9b1","image":"https://cdn.benzinga.com/files/images/story/2026/07/14/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"Johnson & Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead.","category":"company","datetime":1784030120,"headline":"Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’"}, {"id":140895304,"url":"https://finnhub.io/api/news?id=157f7c5da8ff0a5e4f2a825c575e945d68e2085c942ec86685abf546d23b7c5a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply resilience amid tariff influences. Late Stage Chronic Kidney Disease Therapeutics Market Late Stage Chronic Kidney Disease Therapeutics Market Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The \"Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering.The Late Stage","category":"company","datetime":1784016960,"headline":"Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape"}, {"id":140895245,"url":"https://finnhub.io/api/news?id=083d10d3df50abc007cf7a68b661f56bc381dc0eef52cb3dc0a00a03b28e8bf2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The dividend looks secure. The share price is the harder call.","category":"company","datetime":1784016060,"headline":"This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?"}, {"id":140892514,"url":"https://finnhub.io/api/news?id=b85633b633036327b86c0744adb5fccb38fa08d2530290494286e8859a41fa44","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"After hitting fresh all-time highs last week, investors are turning their attention to JNJ's Q2 report, which is scheduled for Wednesday, July 15, before the opening bell.","category":"company","datetime":1783979400,"headline":"Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?"}, {"id":140891291,"url":"https://finnhub.io/api/news?id=70d70f99824f8bcd6503316a221bd6d1b30ecdf59e8dfb17ad8bd115267f3c3b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"(Updates with market moves at the end of the day.) Equities on Wall Street fell Monday, snapping","category":"company","datetime":1783975302,"headline":"Update: Nasdaq Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions"}, {"id":140889992,"url":"https://finnhub.io/api/news?id=5c60b34df24e7ae144e94c72b25a9ce7b052938d9182985218906432e122789c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Social Security benefits come with inflation protection, but the tax formula attached to those benefits does not. For retirees with pensions, IRA withdrawals, taxable investment income, or municipal bond interest, a larger benefit can quietly mean a larger federal tax bill. The result is a tax rule from the 1980s that reaches more retirees every ... How Much of Your Social Security Will You Actually Keep After Taxes?","category":"company","datetime":1783967289,"headline":"How Much of Your Social Security Will You Actually Keep After Taxes?"}, {"id":140889066,"url":"https://finnhub.io/api/news?id=6c4da60e3f458aee87f8080c7136136deca2a95a5b07afe2220895b88f67aaa5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"US benchmark equity indexes were lower intraday, while oil prices jumped as President Donald Trump s","category":"company","datetime":1783966889,"headline":"Equities Fall Intraday, Oil Soars as Trump Reinstates Iranian Shipping Blockade in Hormuz"}, {"id":140888392,"url":"https://finnhub.io/api/news?id=39384362546aba63a4bdfcb9862c1f6ebc3805d8f428319157998c59d8b43bb9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the","category":"company","datetime":1783962000,"headline":"Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight"}, {"id":140888393,"url":"https://finnhub.io/api/news?id=be7524a6a82f777e2943b1fa2d1bdb5a220852a4ed4bc08e478968a3127e2c97","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.","category":"company","datetime":1783960680,"headline":"Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?"}, {"id":140888394,"url":"https://finnhub.io/api/news?id=4d161bbf2ccc3f00b9c0b75fa9af0cd27d948429dd59ab9b9a11b4fe0fb3cd40","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Both Johnson and Johnson and Coca-Cola just beat earnings and both are pulling in capital fleeing tech, but only one of them earns its premium valuation in a world where pricing tailwinds can reverse overnight.","category":"company","datetime":1783959779,"headline":"JNJ Vs. KO: Which Dividend Stock Is The Better Buy?"}, {"id":140888395,"url":"https://finnhub.io/api/news?id=d50a547fa1d3601a3e58d3875738fe9d6e0ce21f3732b749f55851854f20a1a3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"(Bloomberg) -- A federal appeals court revived lawsuits that claim Kenvue Inc. hid alleged risks that Tylenol could cause autism in children whose mothers took the over-the-counter pain medication while pregnant, a controversy that’s roiled the medical community.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Embraces Australian Retirement System Backed by Larry FinkHormuz Route Open Despite Iran Declaration, Maritime Group SaysOpenAI Engineer’s ‘LOL’ Momen","category":"company","datetime":1783956006,"headline":"Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says"}, {"id":140886837,"url":"https://finnhub.io/api/news?id=a694c9a0e95f8d145f8e0632c815b0a0d2b5682d9beaca14a3e4a670f35a44a8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ is set to report second-quarter results on July 15 as investors weigh strong growth drivers, new launches and patent headwinds shaping its long-term outlook.","category":"company","datetime":1783953780,"headline":"Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?"}, {"id":140897508,"url":"https://finnhub.io/api/news?id=782912995a7134b2856f5498ba5653434f29eb8380d197246adc2164cd91a950","image":"","source":"Benzinga","related":"JNJ","summary":"TD Cowen analyst Michael Nedelcovych maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $250 to $300.","category":"company","datetime":1783951773,"headline":"TD Cowen Maintains Buy on Johnson & Johnson, Raises Price Target to $300"}, {"id":140885789,"url":"https://finnhub.io/api/news?id=20ff394bd4bf79df2f0b55793c6a2702ed9a9f3f019a739fe68f85e68c88bc15","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"An $80,000 salary is not the same as $80,000 of spendable income. Federal withholding, FICA taxes, state income taxes where they apply, and retirement contributions all reduce the number that actually reaches checking. For a single filer in a no-income-tax state, 2026 take-home pay on an $80,000 salary would be about $65,100 before retirement contributions, ... Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account","category":"company","datetime":1783950887,"headline":"Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account"}, {"id":140888226,"url":"https://finnhub.io/api/news?id=2fc7e2002ab8e39cabb3974c06cad1fde6ceec9d2584a7770aa6b20f081d01e9","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184220601/image_2184220601.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Build a resilient dividend income portfolio with quality stocks & ETFs: 3.75% yield, low payout ratios, low beta, and defensive sector focus. Here's what investors need to consider.","category":"company","datetime":1783950349,"headline":"How To Build A $50,000 Dividend Portfolio In Today's Market"}, {"id":140885768,"url":"https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.","category":"company","datetime":1783948326,"headline":"How Does LLY Stock Reach $2,100?"}, {"id":140885760,"url":"https://finnhub.io/api/news?id=734257c65af1e4a45e054a81f546b19b506aa280c7ec495b4ea647dd16f3139c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"(Updates with recent oil price movement, world markets' overview and corporate stock movements.)","category":"company","datetime":1783946963,"headline":"Update: US Equity Futures Drop Pre-Bell as Iran Says Strait of Hormuz Closed Once Again, Oil Prices Jump"}, {"id":140885670,"url":"https://finnhub.io/api/news?id=550549e70d592f1616b71600c3535938a693ddd64a3aa9d85eaf5bda54146da8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15","category":"company","datetime":1783945817,"headline":"The Real Case for Buying Johnson & Johnson (JNJ) Before July 15"}, {"id":140885778,"url":"https://finnhub.io/api/news?id=f8ad9fe1cdc29ab2e704c003f47d60e87729cfe29b01ce96258361c5da2e9bee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"US equity futures were lower pre-bell Monday as hostilities continued to re-escalate in the Middle E","category":"company","datetime":1783943964,"headline":"US Equity Futures Drop Pre-Bell as Iran Says Strait of Hormuz Closed Once Again, Oil Prices Jump"}, {"id":140885766,"url":"https://finnhub.io/api/news?id=db128b9932184c522216eea679afd213facf746d65ac46821262b27fe9249c59","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The benchmark US equity measures were pointing lower before the opening bell Monday amid rising tens","category":"company","datetime":1783943685,"headline":"Equity Futures Down Amid Middle East Tensions; Key Earnings on Deck"}, {"id":140884988,"url":"https://finnhub.io/api/news?id=7ba6010589532f31957cbc01d14660bf4b1be15d94fec0bd8703f6a17977156b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A legal career can eventually deliver a six-figure income, but the path is rarely passive. The median annual wage for lawyers was $151,160 in May 2024, and attorneys in higher-paid roles can clear $200,000 or more. The tradeoff is years of training, tuition, billable hours, and pressure that does not disappear when the workday ends. ... This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School","category":"company","datetime":1783939504,"headline":"This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School"}, {"id":140897509,"url":"https://finnhub.io/api/news?id=5e5469c3d9daad982ecb7d2d147a6bd4ac93cffa780187afc15c3d25dc947572","image":"","source":"Benzinga","related":"JNJ","summary":"RBC Capital analyst Shagun Singh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $265 to $287.","category":"company","datetime":1783938127,"headline":"RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $287"}, {"id":140885533,"url":"https://finnhub.io/api/news?id=41b2eb0f4e7cbea05dd165e84c0a30786986d7c1dfbfbbd4b7e79dd8b033872a","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248883890/image_2248883890.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Virtus Equity & Convertible Income Fund (NIE) yields 8.68% with equities/convertibles.","category":"company","datetime":1783935107,"headline":"NIE: High Tech Exposure Poses Risks For This High Yielding CEF"}, {"id":140884402,"url":"https://finnhub.io/api/news?id=7e019bdbd696e4fd6d39936b0e69a10c9989463cd9926bd77fb582cf144e20c1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The math on replacing $60,000 of annual income looks simple until you ask a different question. At a 3.5% yield, you need roughly $1.7 million. At 6%, you need about $1 million. At 12%, you need around $500,000. Three tiers, three price tags, and three very different risk profiles. The trap is treating that choice ... The Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000","category":"company","datetime":1783933237,"headline":"The Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000"}, {"id":140886499,"url":"https://finnhub.io/api/news?id=fe2cc42d718bb0ede68b078e17a8e90e9c2cdfed4ed647b4dee06d264e76c81d","image":"https://cdn.benzinga.com/files/images/story/2026/07/13/Earnings-Season-Written-In-Search-Bar-Wi.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"TSMC, JPMorgan, ASML, Netflix and more report earnings next week. See the options-implied moves, market caps and billions in market value at stake.","category":"company","datetime":1783930923,"headline":"TSMC Could Swing $150 Billion as Options Market Prices Big Moves for This Week’s Earnings"}, {"id":140884397,"url":"https://finnhub.io/api/news?id=745ed4782ce5c544431b119b8ca7a5eb65da0c9a04bb5c6fd8fe63dd1eb87ce9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JPMorgan, Wells Fargo, Citigroup and Bank of America have been highlighted in this Earnings Preview article.","category":"company","datetime":1783926540,"headline":"JPMorgan, Wells Fargo, Citigroup and Bank of America are part of Zacks Earnings Preview"}, {"id":140879806,"url":"https://finnhub.io/api/news?id=907e2e24801890e310d3f807ab81b4d98bbe1b8da7227d4e168237c53a893e67","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Ten years ago, a buyer of Lowe’s (NYSE:LOW) could pick up shares near $66 and collect a quarterly dividend that rose to $0.35 later in 2016. Today, the same share pays $1.25 per quarter, and the stock recently traded near $222. A decade of raises turned a modest-yield holding into a much larger paycheck on ... The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year","category":"company","datetime":1783883349,"headline":"The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year"}, {"id":140879807,"url":"https://finnhub.io/api/news?id=be8a7e25bd648b9d168672c8ccdb1dcebb365f3c11f3d51c03c27b2ed0f9dbe1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Big banks kick off earnings season this week, which will also bring reports from GE Aerospace, Netflix, and Taiwan Semi. In economic news, we’ll get the consumer and producer price indexes, and retail sales data.","category":"company","datetime":1783879200,"headline":"Inflation, Bank of America, Wells Fargo, Goldman, ASML, J&J, and More to Watch This Week"}, {"id":140881859,"url":"https://finnhub.io/api/news?id=0bc2f69608268dd739dda977092c9c1f8e92d222919a3d60f150f4f1cb6a0c29","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Markets face one of the year's most important weeks as Federal Reserve Chair Kevin Warsh delivers his inaugural semi-annual monetary policy testimony before Congress on July 14 and 15.","category":"company","datetime":1783875602,"headline":"Huge Earnings, Inflation Data and Other Key Things to Watch this Week"}, {"id":140877858,"url":"https://finnhub.io/api/news?id=a153814ff186a2d67772186ad8519b068e929e095c5a45e757eeba152fcf1d92","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Two retirees can both pull $100,000 from $2 million income portfolios and still land in very different places after tax. If one stream is mostly qualified dividends and the other is mostly ordinary income, the first retiree may keep about $79,000 after a 15% federal qualified-dividend rate and 6% state tax. The second may keep ... Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes","category":"company","datetime":1783869843,"headline":"Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes"}, {"id":140885726,"url":"https://finnhub.io/api/news?id=f5141d0e31451505d4140e7457dd08d2f99e3b5b999bb70036eb948f3513d9c0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.","category":"company","datetime":1783861500,"headline":"This Dividend ETF Choice Could Shape Your Income Strategy Through 2026"}, {"id":140876376,"url":"https://finnhub.io/api/news?id=a77b6a16e9d7a09cda7e708cd54b49ae5c2a7756f06852dfd9ceedcef2b6af02","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165090199/image_165090199.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Preview key market catalysts this week: big bank earnings, TSM, Netflix, CPI/PPI & Fed testimonyâplus SpaceX valuation insights.","category":"company","datetime":1783838208,"headline":"Wall Street Week Ahead"}, {"id":140872454,"url":"https://finnhub.io/api/news?id=68840e2adea7c97d4c19866e840047b39cd3d0fff9f8a3b7b0302d8e761f5c1e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A 10% dividend feels like a win because it solves the income problem with less capital. The arithmetic is seductive: $80,000 of annual income requires $800,000 at a 10% yield versus about $2.29 million at 3.5%. The catch shows up five, ten, and twenty years later. A fixed high yield may pay more today, but ... The Dividend Growth Plan That Leaves High-Yield Stocks Behind","category":"company","datetime":1783788120,"headline":"The Dividend Growth Plan That Leaves High-Yield Stocks Behind"}, {"id":140871823,"url":"https://finnhub.io/api/news?id=1d9a73da5b10d2eaee3d12ac4534c19ad1480045183ba30d11bd68f651d9a30b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A stock screener sorted by current yield misses one of the most powerful income stories in the market. Microsoft (NASDAQ: MSFT) now pays $0.91 per quarter, up from $0.08 per quarter in 2005. Visa (NYSE: V) most recently paid $0.67 per quarter, and its annual dividend now totals $2.68. Those stocks do not look like ... Why Today’s Small Dividend Could Become Tomorrow’s Retirement Engine","category":"company","datetime":1783783810,"headline":"Why Today’s Small Dividend Could Become Tomorrow’s Retirement Engine"}, {"id":140871834,"url":"https://finnhub.io/api/news?id=768cdf3917b80b9ef071b8c49e6ae5b85e81838d202d4edb8389c64b2806f2a8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Most retirement budgets start with the wrong question. The instinct is to ask, “What yield do I need so the nest egg covers the bills?” Higher yield shrinks the required capital, so the math seduces you toward 8%, 10%, or 12% strategies. Punch in the numbers, write down the smaller portfolio target, and breathe easier. ... The Retirement Budget Most People Build Is Backward","category":"company","datetime":1783779303,"headline":"The Retirement Budget Most People Build Is Backward"}, {"id":140871111,"url":"https://finnhub.io/api/news?id=505b1cf88f9b6b817483c68f62ec48330c62c902fce5eef2592209a03ff95ff7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Most investors panic when stocks turn red, but the losses that actually destroy wealth rarely show up on a bad trading day. Four household-name stocks reveal the quieter threats compounding beneath the surface.","category":"company","datetime":1783772395,"headline":"Volatility Isn’t the Risk You Should Fear — These Are"}, {"id":140871585,"url":"https://finnhub.io/api/news?id=dd79a210b72ec6a7b7f17608596f44d1a1428a0189e4d47e2cb76e5041e2722f","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"JNJ","summary":"Wall Street Week Ahead: key earnings (JPM, BAC, GS), CPI/PPI, retail sales, IPOs & dividendsâget timely stock market updates and plan trades.","category":"company","datetime":1783767600,"headline":"Banking Heavyweights To Kick Off Earnings Next Week"}, {"id":140869911,"url":"https://finnhub.io/api/news?id=bcd8f15ebb03e3568bc541bfac55c5852ab3cd576eba6ef9d27eee8464f7e20b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"There are good reasons to invest in Lilly and to hold off.","category":"company","datetime":1783760640,"headline":"Should You Buy Eli Lilly Stock? Here's My Honest Take."}, {"id":140866925,"url":"https://finnhub.io/api/news?id=75054f2723e01a96eefd1cf2df359e3272c96b78d7d250d2664015f34eed95c4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The big banks dominate this week's reporting docket, though several notable companies from other sectors will also report, including Netflix, Johnson & Johnson, and others. With the outlook trending consistently higher, will companies be able to live up to expectations?","category":"company","datetime":1783722720,"headline":"Q2 Earnings Season Arrives: Can Results Match Upbeat Expectations?"}, {"id":140866928,"url":"https://finnhub.io/api/news?id=1a2a33b52362ea52df721e569171903f9cd957133e2cbc01e06b2b1e08e3ae53","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The Illinois Appellate Court upheld a $45 million talc verdict against Johnson & Johnson. The decision confirms the original jury finding in a talc related case rather than reducing or overturning it. The ruling may influence expectations around ongoing talc litigation and future legal outcomes for the company. For investors following Johnson & Johnson (NYSE: JNJ), this legal outcome arrives while the stock trades at $256.98. The company has recorded a 7.8% return over the past 30 days and...","category":"company","datetime":1783721593,"headline":"Johnson & Johnson (JNJ) Faces Fresh Talc Risk After $45 Million Verdict Stands"}, {"id":140866193,"url":"https://finnhub.io/api/news?id=3f2e5e14bc617aaa8b286e72852f6297e0309a66b1b3633b444202ad357502b5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"DALLAS, July 10, 2026--Dean Omar Branham Shirley, LLP (DOBS), announced today that the Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who developed the deadly disease mesothelioma after decades of using Johnson & Johnson's Baby Powder. This product and other talc-based products have been found to be contaminated with asbestos.","category":"company","datetime":1783715400,"headline":"Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue"}, {"id":140865308,"url":"https://finnhub.io/api/news?id=60c520a5ede9565f971f8e5a2dec91f4f809d6ae9f6eed0f06448f9b4ab0f03e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Replacing $7,500 a month with dividends is a math problem before it is anything else. The number you need to invest depends almost entirely on the yield you chase, and each yield tier carries a different set of tradeoffs that reveal themselves only after you own the position for a decade. Across three broad approaches, ... Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead","category":"company","datetime":1783710033,"headline":"Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead"}, {"id":140863713,"url":"https://finnhub.io/api/news?id=f1b2c2cebd6715831501571f2e0eaa6df6e4dbd5dd50cb7f5e5c18fd5cf66369","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Friday.","category":"company","datetime":1783701603,"headline":"Exploring the top movers within the dow jones index during today's session."}, {"id":140864246,"url":"https://finnhub.io/api/news?id=b1a157383c723c1c371bb7576a64e7316a8e0ae7ac0d7b038f20f7782821f25d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and some stretch past 18. The bill that comes with that lifespan is the part many owners never total, because the monthly receipts feel ... A Dividend Portfolio That Pays For Your Pets","category":"company","datetime":1783701007,"headline":"A Dividend Portfolio That Pays For Your Pets"}, {"id":140864247,"url":"https://finnhub.io/api/news?id=c0977290006aa0018f206464a75fad8cbde03b207ba5408dea5f24fccec7059c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A single weak jobs report moved more money on Wall Street on Monday than any independent company's earnings ever could. That is what played out on Monday, July 6, 2026, and Jim Cramer thinks it handed patient investors a rare opening. The CNBC host argues that big investment funds sold off shares ...","category":"company","datetime":1783700220,"headline":"Jim Cramer recommends buying these 5 stocks"}, {"id":140864232,"url":"https://finnhub.io/api/news?id=91a02918a5278124662a610b3899e8198d2c7971f595e01efcfbf99480df0d7a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.","category":"company","datetime":1783699478,"headline":"Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout"}, {"id":140862791,"url":"https://finnhub.io/api/news?id=9e7c969561b741d7d3e331613b4697e6f1fbaf278c8d61fdd3e72f5aecb85884","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.","category":"company","datetime":1783697402,"headline":"Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner"}, {"id":140862919,"url":"https://finnhub.io/api/news?id=84e711be3858bf2df2c24f171da6d351fd3c2d23dd0caddd1da4b450befeb175","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A dividend cut does not announce itself in advance, but the warning signs appear in the financials long before management steps up to the microphone. Morningstar's index strategists built a three-signal framework to spot the vulnerable payers before the bad news drops.","category":"company","datetime":1783692520,"headline":"5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them."}, {"id":140864870,"url":"https://finnhub.io/api/news?id=7b37f6bd3e286a6ed53bebc2ef7cf932255b8912ecad61b51774df1929604ab6","image":"","source":"Benzinga","related":"JNJ","summary":"B of A Securities analyst Tim Anderson maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $254 to $263.","category":"company","datetime":1783692234,"headline":"B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $263"}, {"id":140864871,"url":"https://finnhub.io/api/news?id=0b230cf4ef13909094f0c290b905986804d9f285937fd22e25e8cdfb17957867","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will","category":"company","datetime":1783690507,"headline":"6 Health Care Stocks With Whale Alerts In Today’s Session"}, {"id":140862907,"url":"https://finnhub.io/api/news?id=cb61a570439a0c8f576f20e29d2c5ae39d694ad9498a3421a02673d39ed5b2dc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"U. S. stock futures traded little changed on Friday as investors paused after Thursday’s technology-led rally, shifting their attention toward next week’s corporate earnings reports and key inflation releases.","category":"company","datetime":1783690270,"headline":"U.S. Futures Drift as Investors Await Earnings Season and Inflation Data: Dow Jones, S&P, Nasdaq"}, {"id":140862921,"url":"https://finnhub.io/api/news?id=1f52f873241b901f657ddaf086aba8d0e482b06569ce93acf95f3cf49f028cd7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Beyond analysts' top-and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.","category":"company","datetime":1783689306,"headline":"Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"}, {"id":140861579,"url":"https://finnhub.io/api/news?id=c62ba8099aee23158987217595678195e0459f312029919472cb27427facb95f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A long-term care policy does not just protect against a future care bill. It also creates a premium bill that may have to be paid for decades. A healthy 55-year-old buying meaningful inflation protection can face annual premiums in the low-to-mid thousands, and a 55-year-old couple can easily cross $5,000 combined. The planning question is: ... What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?","category":"company","datetime":1783689157,"headline":"What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?"}, {"id":140861555,"url":"https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.","category":"company","datetime":1783684953,"headline":"JNJ Stock Keeps Climbing. Should You Climb On?"}, {"id":140860612,"url":"https://finnhub.io/api/news?id=f9459f84a75170feabd63f20cc714d6a53208191cf6f97ca3ab4d9e39210c9f2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"An investor who bought Microsoft (NASDAQ:MSFT) ten years ago paid closer to $50 per share than $45. Those shares now pay $3.64 per year in dividends, based on Microsoft’s current $0.91 quarterly payout. That is a yield on cost of roughly 7%, even though the stock’s current yield is about 1%. The starting yield helped, ... The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet","category":"company","datetime":1783678805,"headline":"The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet"}, {"id":140856624,"url":"https://finnhub.io/api/news?id=d55803321975e4b10ca95fa10513a41f53df3cf2298ded23f8fbd88279d38d63","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Thank you very much for attending! Question Answer Lots of reverb! Close zoom down and re-open the webinar Interesting issue of whether bio/medical, software, financials, small caps are just a rotation play versus an enduring trend, and whether AI is going to trend back up or just chop around Great Q. Might be yes and yes. Thx Cheers Bill, thank...","category":"company","datetime":1783636387,"headline":"Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026"}, {"id":140854683,"url":"https://finnhub.io/api/news?id=f48afeae7fe86586e22a6c2aef80e8770dc29470f4a033873690b6b6dcd5c88a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Twelve thousand dollars a month sounds like a round number, but it carries weight. It works out to $144,000 a year, a little more than twice the U.S. per capita disposable personal income of $68,391 reported for the first quarter of 2026. Replacing that with portfolio income, rather than a paycheck, is a math problem ... How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?","category":"company","datetime":1783623661,"headline":"How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?"}, {"id":140854599,"url":"https://finnhub.io/api/news?id=8a44172a2c0a8c1d20ba64981814906cb14203408f47f6475ad9da0de38e5b23","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A sharp sector rotation has knocked down some of the market’s steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome. On the July 6 episode of Mad Money, Cramer framed the pullback this way: “These rotations create dislocations that seem to ... Jim Cramer: Buy the Dip on These 3 Stocks Now","category":"company","datetime":1783622728,"headline":"Jim Cramer: Buy the Dip on These 3 Stocks Now"}, {"id":140852952,"url":"https://finnhub.io/api/news?id=0d784b8700baa9952e6e2725c6aabb3cd5fb07a43fc8a07af17486eee4f010a8","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"JNJ","summary":"Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.","category":"company","datetime":1783615204,"headline":"Top dow jones movers in Thursday's session"}, {"id":140853492,"url":"https://finnhub.io/api/news?id=a5af371c02f60aeaa2d1eae5f1e19dfac605beab7016a9f36c7f7c3abf491182","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1783613403,"headline":"Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?"}, {"id":140853417,"url":"https://finnhub.io/api/news?id=62b81d8d0d53fd3db3259bb6e645f20539ac41acef8be993c15f401fc48764d2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Fundstrat’s Tom Lee returned to CNBC’s Morning Call Sheet on Thursday, July 9, alongside JonesTrading’s Mike O’Rourke and Vital Knowledge’s Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names. Lee argued: “AI is probably one of the most important structural stories in our lifetime.” ... Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally","category":"company","datetime":1783612638,"headline":"Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally"}, {"id":140852126,"url":"https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.","category":"company","datetime":1783609118,"headline":"Make Your AMGN Shares Pay You 8.7% While You Hold Them"}, {"id":140852127,"url":"https://finnhub.io/api/news?id=3dc0ae22f59ecc076a1a15b91bdc68fa65b5f68b674058d014aa38fddece5920","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.","category":"company","datetime":1783604422,"headline":"The Wide Chasm Priced Into Boston Scientific Stock"}, {"id":140854329,"url":"https://finnhub.io/api/news?id=f85d59ff5cf636e53f4a04b2a9899cbee55215709e026bf0dbff25839923e5cd","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536","source":"Benzinga","related":"JNJ","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often","category":"company","datetime":1783604108,"headline":"9 Health Care Stocks With Whale Alerts In Today’s Session"}, {"id":140850835,"url":"https://finnhub.io/api/news?id=9966738aa03e2c1d7bf64189594dd665e4ed1896a9b982f1abb0e878f0e60f2b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The options market has priced a sizable range of outcomes for the surgical robotics leader, and if you hold the shares, you are already carrying that full exposure.","category":"company","datetime":1783603762,"headline":"Just How Much Risk Is Built Into ISRG Stock?"}, {"id":140850812,"url":"https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.","category":"company","datetime":1783602824,"headline":"ABBV Leads Its Peer Group. You Pay For That"}, {"id":140850717,"url":"https://finnhub.io/api/news?id=5da71b8500b2edec56fc992ba44bfbf9dd1381fc160d75a661b1ff23ffbfe7d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The retirement income math often starts in the wrong place. A retiree who wants $60,000 a year might divide that figure by a portfolio yield and assume the highest yield is the most efficient path: about $1.71 million at 3.5%, $857,000 at 7%, or $500,000 at 12%. On day one, the 12% portfolio looks like ... Why the Best Retirement Paycheck May Start Smaller Than You Expect","category":"company","datetime":1783602306,"headline":"Why the Best Retirement Paycheck May Start Smaller Than You Expect"}, {"id":140850838,"url":"https://finnhub.io/api/news?id=21dfd1aef1dc45094c955dfaeda9d3db8bbf9707517c7c6b649519abe0893c0f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The math is simple. A $1 million portfolio generating $100,000 in annual income requires a blended yield of 10%. That is achievable today, but only by leaning hard into the aggressive end of the dividend spectrum. The question this article answers: what does that portfolio actually look like, and what happens when the highest yielder ... How a $1 Million Dividend Portfolio Can Generate $100,000 Annually","category":"company","datetime":1783600234,"headline":"How a $1 Million Dividend Portfolio Can Generate $100,000 Annually"}, {"id":140850839,"url":"https://finnhub.io/api/news?id=4b0791faccaebf7adbccb171e2c837a1133100a353457857d7946eac73d54b84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted the AI opportunities in neoclouds. Cramer was bullish on the stock and expects positive developments for the company, as he stated: You’re going to see some massive moves in real time for no reason whatsoever. Why do we care […]","category":"company","datetime":1783599522,"headline":"Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”"}, {"id":140849942,"url":"https://finnhub.io/api/news?id=15fd3b700ed22c2dea115cbfc7c32543943c91b74084964d3e78b6e2fec65771","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A $60,000 retirement paycheck sounds like a single target, but a portfolio can produce it in very different ways. A lower-yield portfolio demands more capital upfront but may give the income room to grow. A high-yield portfolio can shrink the capital requirement, but it usually asks the investor to accept more credit risk, distribution risk, ... The Retirement Portfolio That Pays You Without Demanding Constant Attention","category":"company","datetime":1783597685,"headline":"The Retirement Portfolio That Pays You Without Demanding Constant Attention"}, {"id":140852128,"url":"https://finnhub.io/api/news?id=0d8d5355ebff870c994dea78b71564f062bb6a51ab8e04cbf1a91b3ad27b8cd6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.","category":"company","datetime":1783591200,"headline":"J&J wins FDA approval for dual-energy ablation catheter"}, {"id":140850500,"url":"https://finnhub.io/api/news?id=abd5251e75e6785b9c62af971b1d6f692745a5486eed4c6d763d18f9e5bce35f","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248458314/image_2248458314.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Stryker (SYK) buy rating after a rare Q1 miss from a temporary cyber disruption. Full-year guidance holds; demand strong.","category":"company","datetime":1783588719,"headline":"Stryker: The Market Is Overreacting To One Disrupted Quarter"}, {"id":140848104,"url":"https://finnhub.io/api/news?id=3d852d8e32a79f75a1edee40b96b8722f59a65a19453849ad4e440bf4c3ebdfa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"A share of Johnson & Johnson (NYSE: JNJ) paid $0.25 per quarter in dividends in 1999. That same share pays $1.34 per quarter in 2026. The stock price has moved through plenty of cycles since then, but the income stream alone has more than quintupled without the investor doing anything except holding. That trajectory is ... The Case For Buying Smaller Dividends That Grow Faster","category":"company","datetime":1783575229,"headline":"The Case For Buying Smaller Dividends That Grow Faster"}, {"id":140847016,"url":"https://finnhub.io/api/news?id=e615909c47c3bbca4e783286acbb04544f11c6c9106c7cb4982ae31045c50f1d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson recently received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an ablation catheter that can deliver both radiofrequency and pulsed field energy through a single device, integrated with the CARTO mapping ecosystem, with U.S. procedures set to begin following a phased commercial rollout this summer. This dual-energy, single-catheter approach could deepen Johnson & Johnson’s position in advanced electrophysiology by simplifying workflows for...","category":"company","datetime":1783559555,"headline":"Dual-Energy EP Catheter Approval Could Be A Game Changer For Johnson & Johnson (JNJ)"}, {"id":140846321,"url":"https://finnhub.io/api/news?id=08f4b8e626af283395b79b6ad9d14df1b68dff29ce2866c801399bf9a1063791","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.","category":"company","datetime":1783547104,"headline":"Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors"}, {"id":140843362,"url":"https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri","category":"company","datetime":1783529860,"headline":"Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"}, {"id":140843377,"url":"https://finnhub.io/api/news?id=0c81e90fd0177693e04c6f597f3094721aad21cf484f4f5e2f07a9365658f254","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"If you hold shares in this surgical robotics leader, you are already carrying a sizable two-sided risk, whether you trade options or not.","category":"company","datetime":1783528899,"headline":"Just How Wide Is The Path Ahead For Intuitive Surgical Stock?"}, {"id":140853485,"url":"https://finnhub.io/api/news?id=7b86bbff6fb3fc6485d7790cc61a4572282dd3e8f99f0b1c923747f3f413dee6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.","category":"company","datetime":1783528500,"headline":"The Market Just Got Shaken—These 3 ETFs May Come Out Stronger"}, {"id":140841778,"url":"https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.","category":"company","datetime":1783524984,"headline":"The Wide Divide Ahead For Eli Lilly Stock"}, {"id":140841649,"url":"https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th","category":"company","datetime":1783523510,"headline":"Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"}, {"id":140843952,"url":"https://finnhub.io/api/news?id=3018272f12e8143d30f18b292420d5c4acbe0d3d8e83b86b9588d1bebf4876ac","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253448108/image_2253448108.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Legend Biotech Corporation outlook: Carvykti drives upside in multiple myeloma, plus LB2501 optionality. Click for this updated look at LEGN stock.","category":"company","datetime":1783521966,"headline":"A New Look At Legend Biotech: Plenty Of Upside For Carvykti"}, {"id":140853129,"url":"https://finnhub.io/api/news?id=986b3d1d89892df81985808d7bbb42421da3007c0a3099065e808f565579d207","image":"https://image.cnbcfm.com/api/v1/image/108332264-17835331231783533120-47039073227-1080pnbcnews.jpg?v=1783533122&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"Victoria Greene, G Squared Private Wealth, joins 'The Exchange' to discuss how investors should position, which type of stocks to favor and much more.","category":"company","datetime":1783520303,"headline":"Favor Nvidia and Apple now as they are capex light, says G Squared's Victoria Greene"}, {"id":140853203,"url":"https://finnhub.io/api/news?id=cd79bc33512abc2a735e65d0de5a0445a51d2b2210e7df8dae0a272af1adbec7","image":"https://image.cnbcfm.com/api/v1/image/108332252-17835317791783531776-47038724915-1080pnbcnews.jpg?v=1783531778&w=1920&h=1080","source":"CNBC","related":"JNJ","summary":"Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the dealmaking cycle and much more.","category":"company","datetime":1783517749,"headline":"Dealmaking in biotech sector has brought an extreme technical breakout, says UBS' Michael Yee"}, {"id":140842821,"url":"https://finnhub.io/api/news?id=121f9254926761f799768afd3501c8a7b8a784f3ac016fea40973077011d85b5","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2284613261/image_2284613261.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, timeline, & upside. Click for a CMPS stock update.","category":"company","datetime":1783517032,"headline":"Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission"}, {"id":140846016,"url":"https://finnhub.io/api/news?id=e31a1ac212d068a0cdeb4424eac924a6439cf98b06cf1eab8753dbc3164925c8","image":"","source":"Benzinga","related":"JNJ","summary":"Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $283 to $284.","category":"company","datetime":1783515518,"headline":"Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $284"}, {"id":140840466,"url":"https://finnhub.io/api/news?id=ba0edb8678292f7637ad16b2934dae337c3ef3760794d05a61f7e4f34e6b582c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.","category":"company","datetime":1783513980,"headline":"3 Cancer Stocks to Watch as Oncology Innovation Accelerates"}, {"id":140839590,"url":"https://finnhub.io/api/news?id=0b3f1e61efb1fb0820fb42c400f359822f8c4ff3603783802b2e65fb1846e0a7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"IRVINE, Calif., July 08, 2026--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform","category":"company","datetime":1783511100,"headline":"Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform"}, {"id":140846017,"url":"https://finnhub.io/api/news?id=22d5ef0d95b8c47e4b8dcb1c4c7da0d6de852a0852d139fc9de9542768ac57fb","image":"","source":"Benzinga","related":"JNJ","summary":"Citigroup analyst Joanne Wuensch maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $285 to $298.","category":"company","datetime":1783510883,"headline":"Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $298"}, {"id":140839591,"url":"https://finnhub.io/api/news?id=de549ecb2af71266d774d1161f4e028d20e3fc0e0b1f3120348e1e8ee1e12921","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"The average American household spent $78,535 in 2024, according to the latest Bureau of Labor Statistics Consumer Expenditure Survey. Round that to $80,000, and you have a useful starting point for the retirement paycheck many households may need to replace. Gross salary can overstate the target because it includes payroll taxes, retirement contributions, and expenses ... How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing","category":"company","datetime":1783509106,"headline":"How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing"}, {"id":140839535,"url":"https://finnhub.io/api/news?id=7726ae2cdedb1c33a615b6638f4e25f37fdd8dc901db4aa554334e0691a5e29e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"JNJ","summary":"Turning $500,000 into $100,000 of annual income requires a 20% yield, and no durable, diversified income portfolio should be built around that assumption. Anyone quoting a number that high is usually taking on extreme risk, relying on leverage, or handing back some of your own capital. The dividend-growth formula solves a different equation. It accepts ... The Dividend Growth Formula That Turns $500,000 Into a Six-Figure Income Stream","category":"company","datetime":1783505506,"headline":"The Dividend Growth Formula That Turns $500,000 Into a Six-Figure Income Stream"}, {"id":140839793,"url":"https://finnhub.io/api/news?id=303ee684ee433beba364a488812c644cbdf27564c78a5b59a237e3643f317e29","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172700619/image_2172700619.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Stryker stock looks undervalued with a 13% discount to fair value, a strong EPS growth outlook, and dividend potential. Click for more on SYK stock.","category":"company","datetime":1783497600,"headline":"Stryker: Medtech On Sale, Benefiting From Industry Growth"}, {"id":140846018,"url":"https://finnhub.io/api/news?id=330e695f6a29c90eab3bbf4a2ab26fe5511bb4c8042095c2e87876f6200ea29d","image":"","source":"Benzinga","related":"JNJ","summary":"The Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single","category":"company","datetime":1783496808,"headline":"Johnson & Johnson Receives FDA Approval For Its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Platform"}, {"id":140839188,"url":"https://finnhub.io/api/news?id=8d92f502e9ae3cee37efc06a64a391481098d0484fdfdf8c42da0d4610d75f7d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266159674/image_2266159674.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"JNJ","summary":"Johnson & Johnson has the momentum on its side and it is possible for the stock to increase further. Find out why JNJ stock is a hold.","category":"company","datetime":1783493220,"headline":"Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism"}

data_source finnhub_news_keyword_model

article_count 8

negative_hits 0

positive_hits 3

recomputed_at_score true

sentiment_score_raw 0.9

source_article_count 245

discarded_article_count 224

sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib

基本面 4.4 5/110 88% 4.4

資金流 6.8 20/110 34% 6.8

市場環境 7.2 15/110 48% 7.2

催化劑 2 20/110 10% 2

風險管理 7 10/110 70% 7

技術信號 16.8 30/110 56% 16.8

情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 0/50

ret_5d -0.0347

max_score 50

max_total 50

raw_total 0

vcp_bonus 0

vol_ratio 0.8677

ret_points 0

vol_points 0

range_ratio 0.9704

volat_points 0

day_range_pct 0.0223

model_version cursor_18_27_news_v2_160

available_bars 30

breakout_points 0

partial_history false

pullback_points 0

breakout_vol_bonus 0

first_breakout_20d false

return_window_days 5

first_breakout_bonus 0

breakout_quality_points 0

Risk management

level Medium

reason risk management score >= 6.5/10

position

score 1.8

details

atrPct 2.6131

turnoverUsdM 2018.3408

liquidityPoints 0.8

volatilityPoints 1

rrPoints 1.4

stopLevels

symbol US.JNJ

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 235.8164

strength_details

ma_score 1.5

atr_score 2

rsi_score 1

macd_score 1.5

volume_score 1

market_adjustment 1

risk_reward_ratio 1

stop_loss_percent 5.2

take_profit_price 261.261

target_multiplier 1.6

technical_strength 1.38

take_profit_percent 5

positionPoints 1.8

stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.2

stopLossPercent 5.2261

diversificationPoints 2

Calculation audit log

基本面分析總分: 4.4/5分
資金流分析總分: 6.8/20分
市場環境分析總分: 7.2/15分
催化劑分析: 2/20分
風險管理總分: 7/10分
技術信號分析總分: 16.8/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx

value 78.57

atr

atr 6.5018

rule ATR / current price; lower volatility scores higher

score 6

atr_pct 2.61

cci

rule Cursor_18.24 CCI bands

level 弱勢

score 4

value -22.84

cmf

rule Cursor_18.24 CMF bands

level 平衡

score 4

value 0.0873

kdj

d 30.93

j 2.79

k 21.55

rule Cursor_18.24 K/D cross

score 0

signal 死叉

mfi

rule Cursor_18.24 MFI bands

level 超賣或超買風險

score 2

value 24.56

obv

rule Cursor_18.24 recent_slope vs previous_slope

score 4

trend 弱勢

value 6943650

recentSlope -2062335

previousSlope 6332850

rsi

value 41.54

sar

rule Cursor_18.24 Parabolic SAR

score 4

trend 下降

value 264.4554

position SAR喺價上

distancePct 6.28

previousTrend 下降

ma50

value 239.143

macd

macd 3.741

trend 中性偏多

signal 5.5144

histogram -1.7733

vwap

rule Cursor_18.24 VWAP 20D consecutive close

score 2

value 252.0049

position <VWAP

consecutiveAbove 0

volume

rule Cursor_18.24 volume ratio

level 無力

ratio 0.92

score 4

avgVolume 8804468

currentVolume 8111650

derived

ma20 252.8465

ma50 239.143

prevClose 253.04

avgVolume10 8278585

avgVolume20 8804468

changePercent -1.67

avgVolumeForScore 8804468

ma_cross

ma20 252.8465

ma50 239.143

rule Cursor_18.24 MA20/MA50 cross

cross 多頭

score 4

prevMa20 251.825

prevMa50 238.659

spreadPct 5.73

isVolumeBreakout false

bollinger

lower 235.5241

upper 270.1689

position 中間

rsi_short

value 31.27

macd_short

macd 0

trend 中性

signal 0

histogram 0

volume_ratio

ratio 0.92

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.613053508035789,
        "turnoverUsdM": 2018.3408341165,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 235.8164,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.2,
      "take_profit_price": 261.261,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.226107016071578,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 48.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 0
  },
  "market": {
    "ma20": 252.8465,
    "ma50": 239.143,
    "close": 248.82,
    "prevClose": 253.04,
    "avgVolume20": 8804468,
    "volumeRatio": 0.92,
    "changePercent": -1.67
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 0,
    "details": {
      "ret_5d": -0.034720798957241006,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 0,
      "vcp_bonus": 0,
      "vol_ratio": 0.8677069544172116,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.9704401493558146,
      "volat_points": 0,
      "day_range_pct": 0.022285185182654786,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 48.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 88,
        "contribution": 4.4
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 7.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 48,
        "contribution": 7.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 16.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56,
        "contribution": 16.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 48.2,
    "details": [
      "基本面分析總分: 4.4/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 7.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 16.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.4,
      "資金流": 6.8,
      "市場環境": 7.2,
      "情緒分析": 4,
      "技術信號": 16.8,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 2018.3408341165,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 0.8,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.77
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.11750425,
                "ma50": 719.0110022000002,
                "name": "QQQ",
                "close": 696.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.7885068500001,
                "ma50": 744.54560184,
                "name": "SPY",
                "close": 742.090027,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.613053508035789,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140953052,
                "url": "https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...",
                "category": "company",
                "datetime": 1784477270,
                "headline": "Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140914232,
                "url": "https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.",
                "category": "company",
                "datetime": 1784149262,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."
              },
              {
                "id": 140912735,
                "url": "https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...",
                "category": "company",
                "datetime": 1784131079,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140909593,
                "url": "https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...",
                "category": "company",
                "datetime": 1784128337,
                "headline": "Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"
              },
              {
                "id": 140909601,
                "url": "https://finnhub.io/api/news?id=b5061df4902a47af987466427333da6c9fe92bdb416e459fa06f1c832924ea69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1784122204,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 140908262,
                "url": "https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784115002,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"
              }
            ],
            "raw_source": [
              {
                "id": 140964880,
                "url": "https://finnhub.io/api/news?id=12a8abdbc76bf7f5d75a741fcb8bf92b1169e627404cdd9748c5e4427653cfaf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read what's driving outlook.",
                "category": "company",
                "datetime": 1784578140,
                "headline": "Top Analyst Reports for Johnson & Johnson, Lam Research & Seagate"
              },
              {
                "id": 140963421,
                "url": "https://finnhub.io/api/news?id=6ea0dd033658292f48582a592a40caa31066d357172a543dd20d199c2861cc74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.",
                "category": "company",
                "datetime": 1784574905,
                "headline": "The Robot Maker's Paradox"
              },
              {
                "id": 140962978,
                "url": "https://finnhub.io/api/news?id=02b2e30e4b5a8015da142e1b9a1f892637cc927d311f40cc472a5668f9bca33d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1784574604,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140963423,
                "url": "https://finnhub.io/api/news?id=26047126ae59bd8c4eb72c217ec847dd194744894cd020aa98db1bbb6da3a19e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.",
                "category": "company",
                "datetime": 1784571665,
                "headline": "What's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?"
              },
              {
                "id": 140963424,
                "url": "https://finnhub.io/api/news?id=589a1dde19072b6d106740e598d7398a3c273b730e0ffb276308b41b42040853",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.",
                "category": "company",
                "datetime": 1784570231,
                "headline": "Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD"
              },
              {
                "id": 140963405,
                "url": "https://finnhub.io/api/news?id=953f03a95ac4369d23919084ddcefbfe8771f49595f8b6d1dbc914ca7cd2fca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784569523,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140960594,
                "url": "https://finnhub.io/api/news?id=b6dc2875bc5307f0ba48199fbd747c6354cd7ce2ee06b8136a7e109730aa2ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?",
                "category": "company",
                "datetime": 1784551980,
                "headline": "Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?"
              },
              {
                "id": 140959509,
                "url": "https://finnhub.io/api/news?id=c8528b8311704302ec45b4ffa65ff0f68ee49d76d3993cfcb752857c60ab52b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LQDA, BILL and Colgate-Palmolive highlight recent Zacks picks as multiple portfolios outperformed or posted strong stock gains despite market volatility.",
                "category": "company",
                "datetime": 1784550840,
                "headline": "Beat the Market the Zacks Way: Liquidia, BILL, Colgate-Palmolive in Focus"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140958951,
                "url": "https://finnhub.io/api/news?id=5ed9acc8832a619e0dcafb8eca77d97a1e2404577fca62c7969d2a1bbc22ad55",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "ImmunityBio (IBRX) cautious buy: Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise riskâread now.",
                "category": "company",
                "datetime": 1784536225,
                "headline": "ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)"
              },
              {
                "id": 140958130,
                "url": "https://finnhub.io/api/news?id=ec6706319150549ddafa63e0a3db84a31d57f725ac1deda3893c213e428ab5e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.",
                "category": "company",
                "datetime": 1784534400,
                "headline": "Bear of the Day: J&J Snack Foods (JJSF)"
              },
              {
                "id": 140957651,
                "url": "https://finnhub.io/api/news?id=b48119d669b046cb291e67f2f812348161794131c0b00f6b915027443a57822d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784527200,
                "headline": "What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment."
              },
              {
                "id": 140955522,
                "url": "https://finnhub.io/api/news?id=8d88b130ffa95c1632bba1a2a2e600b109439fdb1e85c0c8ffa6f37540cd5258",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J has more than 28 sources of blockbuster revenue.",
                "category": "company",
                "datetime": 1784500200,
                "headline": "Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?"
              },
              {
                "id": 140954711,
                "url": "https://finnhub.io/api/news?id=bd7f9275f6da066da0e062bbc8c0c2967aae456c9c00c3c32cd0ef0849b285c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "They can help stabilize your portfolio in these otherwise volatile times.",
                "category": "company",
                "datetime": 1784492400,
                "headline": "My 2 Favorite Dividend Kings to Buy Right Now"
              },
              {
                "id": 140953052,
                "url": "https://finnhub.io/api/news?id=67eeee0773b2fcf0a7f7695994ba789e51fa6c55cddd961ffbccaed06e0cc8b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...",
                "category": "company",
                "datetime": 1784477270,
                "headline": "Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device"
              },
              {
                "id": 140951671,
                "url": "https://finnhub.io/api/news?id=edcfdddd5026455494e57595a336d293ee28d8d9a3b6d45f94f6c9f02447669b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.",
                "category": "company",
                "datetime": 1784467858,
                "headline": "3 Biggest Pharma Giants: Buy, Sell or Hold?"
              },
              {
                "id": 140951727,
                "url": "https://finnhub.io/api/news?id=4ae5fefce3d887eea60615731dbad10a3cf82c75257323d81f2e4c81c3a0cde3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.",
                "category": "company",
                "datetime": 1784466389,
                "headline": "Would You Rather Earn $55,000 Today or $110,000 in 20 Years?"
              },
              {
                "id": 140951073,
                "url": "https://finnhub.io/api/news?id=fafc6aeb110fdd02064f73a91ea365091609ea30e4fb379d6dcb9508affe1c6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.",
                "category": "company",
                "datetime": 1784458843,
                "headline": "From a $38,000 Income to $84,000 Without Investing Another Dollar"
              },
              {
                "id": 140950551,
                "url": "https://finnhub.io/api/news?id=f01b55cce75788117c7e394aa1e666da2acbea913eccbbe07be2af1e72923c65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Headline inflation keeps rising faster than Social Security adjustments, quietly shrinking what retirement actually buys. A small, dedicated portfolio sleeve could fund those annual increases entirely from income, but the tier you choose changes everything about how much capital you actually need.",
                "category": "company",
                "datetime": 1784452337,
                "headline": "The Portfolio That Lets You Ignore Inflation"
              },
              {
                "id": 140943803,
                "url": "https://finnhub.io/api/news?id=0dc2c819466c7138315ffa76be796026e4c9152e78e0aa2ecd3903decb24e813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.",
                "category": "company",
                "datetime": 1784387281,
                "headline": "The Portfolio That Gives You a $2,000 Raise Every Year"
              },
              {
                "id": 140943075,
                "url": "https://finnhub.io/api/news?id=967d9cb8efa721530bf134eb3b72fb54af112a8dce5b14647ab21b605e484810",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.",
                "category": "company",
                "datetime": 1784379647,
                "headline": "The Portfolio That Lets You Cruise Through the News, Unbothered"
              },
              {
                "id": 140943050,
                "url": "https://finnhub.io/api/news?id=b6726c67b6d318f590ea801e8e23e38a41d664def7724f009c1732cc043834e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.",
                "category": "company",
                "datetime": 1784376045,
                "headline": "3 Dividend Stocks That Have Survived Every Market Crash in July"
              },
              {
                "id": 140942415,
                "url": "https://finnhub.io/api/news?id=c189e19fb9e0837e2ced094a748f8a447c86c96f6cd670336ac539cab7f21005",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Lifelong learning sounds like a noble habit until you price it out across decades and realize it behaves more like a recurring expense than a one-time splurge. The portfolio that funds it may look nothing like the obvious choice.",
                "category": "company",
                "datetime": 1784373097,
                "headline": "Here’s the Funding It Takes to Keep Learning Forever"
              },
              {
                "id": 140951072,
                "url": "https://finnhub.io/api/news?id=73534d700060689b3f3e12bb0a8fd766db23bf8c5f3b1546e2cec50941fb3bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.",
                "category": "company",
                "datetime": 1784372400,
                "headline": "MarketBeat Week in Review – 07/13- 07/17"
              },
              {
                "id": 140939403,
                "url": "https://finnhub.io/api/news?id=57d40fe7bb5c8aac6f79be0256a9f813474876b809b4a24f9b6e6987567d036e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.",
                "category": "company",
                "datetime": 1784333456,
                "headline": "If Volatility Stays Low, Here’s What Happens to DIVO’s Monthly Income"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140937906,
                "url": "https://finnhub.io/api/news?id=a0e0cf5d5229803aafd81bc10762576800986410f1c10defc757f88a1be078dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer named five blue-chip stocks the market punished after strong earnings, and he's betting that millions of investors and billions of dollars got it completely wrong.",
                "category": "company",
                "datetime": 1784322864,
                "headline": "Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks"
              },
              {
                "id": 140937907,
                "url": "https://finnhub.io/api/news?id=544c9a5b6ab515dd6fe654dd847834a8214c9a346b18b078ca02fbcb4330a814",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.",
                "category": "company",
                "datetime": 1784322800,
                "headline": "Jim Cramer Says Oracle Is “Going Down” and Avoid Every Liquor Stock. Here’s What He’d Buy Instead"
              },
              {
                "id": 140936306,
                "url": "https://finnhub.io/api/news?id=9379fd9a229dde89bca8d1d8f41d09e6f5b887ee5f712f95edadbe7a94d281c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.",
                "category": "company",
                "datetime": 1784315450,
                "headline": "DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch"
              },
              {
                "id": 140935746,
                "url": "https://finnhub.io/api/news?id=b8d366b0978045461c3e2f0f805013981ee50b4718778eb2469f0e71bb1d2514",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784315404,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140934459,
                "url": "https://finnhub.io/api/news?id=a2ee62a66c63a946d94c3e6beb499c40b3125181a2923f5fa2fc732d6e9e4955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.",
                "category": "company",
                "datetime": 1784307459,
                "headline": "VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way"
              },
              {
                "id": 140933705,
                "url": "https://finnhub.io/api/news?id=cf957e631b08afbc352ac0c9645261668019b12720ed7857cae855b3ae4f2250",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784306404,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140933340,
                "url": "https://finnhub.io/api/news?id=dc6646e28e14b3fdaff43894e8f7f8bbb22af0391c056fc946d02d9e5a21b04b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.",
                "category": "company",
                "datetime": 1784304654,
                "headline": "SPYI Investors: Watch These 2 Macro Factors Before the Next Distribution"
              },
              {
                "id": 140932972,
                "url": "https://finnhub.io/api/news?id=88bacf0e7e75d7ad7490cf737b97af9956511d5def5cdbef0d549d91e59d52d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?",
                "category": "company",
                "datetime": 1784302670,
                "headline": "Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?"
              },
              {
                "id": 140932973,
                "url": "https://finnhub.io/api/news?id=0504e442cf7f265bb43b0e44d54c0386af3ed0aa7fd4f592d362e90177bbdfa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.",
                "category": "company",
                "datetime": 1784298660,
                "headline": "J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why"
              },
              {
                "id": 140931435,
                "url": "https://finnhub.io/api/news?id=43bdff8a716708433fb4dc9ca77c1f32465999080349e9d6bee352b6884763f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.",
                "category": "company",
                "datetime": 1784295671,
                "headline": "Stock Market Today: Nasdaq Leads Indexes Down; SpaceX Slides As Flight Canceled (Live Coverage)"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140931564,
                "url": "https://finnhub.io/api/news?id=c1f3439f3f31bb5e63491154cf43bcb3dc1f5d6f47086643b3ecba50b2f29e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.",
                "category": "company",
                "datetime": 1784289180,
                "headline": "Why This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Years"
              },
              {
                "id": 140930733,
                "url": "https://finnhub.io/api/news?id=2f16834b08c6c17f3fe26ebf1ea738c1f438efeb6aa48d5eb4eb3ba6a91c9cde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A portfolio that pays $27,000 a year in dividends sounds modest. Left alone for a little more than a decade of steady dividend growth, that same income stream can quietly grow toward $66,000 without a single additional dollar of savings. That is the basic appeal of dividend growth investing: the arithmetic of today’s yield matters, ... Growing an Income Tree: From $27,000 to $66,000",
                "category": "company",
                "datetime": 1784286034,
                "headline": "Growing an Income Tree: From $27,000 to $66,000"
              },
              {
                "id": 140934862,
                "url": "https://finnhub.io/api/news?id=9254cbc0007632f41e4f18a578ee59d8ca248cce6c424d6e754fd2559e0baa3e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Guggenheim  analyst Vamil Divan   reiterates Johnson &amp; Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.",
                "category": "company",
                "datetime": 1784277291,
                "headline": "Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target"
              },
              {
                "id": 140926081,
                "url": "https://finnhub.io/api/news?id=e64f76c09adafa515f4830316766b320a68890737e1611bda2f9562417d8f44b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.",
                "category": "company",
                "datetime": 1784236020,
                "headline": "Why Healthcare Stocks Look Like a Haven in This Market"
              },
              {
                "id": 140934035,
                "url": "https://finnhub.io/api/news?id=582214e1504528124d4be9c4af6af3802955bcbb5b2ad89b6f8829dfea0ac010",
                "image": "https://image.cnbcfm.com/api/v1/image/108336317-5ED3-MM-A-BLOCK-071626.jpg?v=1784242037&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer talks going against the grain in the market.",
                "category": "company",
                "datetime": 1784231304,
                "headline": "Jim Cramer: It takes a lot of guts to disagree with the market about a stock after it reports"
              },
              {
                "id": 140924324,
                "url": "https://finnhub.io/api/news?id=d4761d29e079ca2623b2595a2c5f2d57d077d95edfc51ae51e3148fa11e22d4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.",
                "category": "company",
                "datetime": 1784224421,
                "headline": "Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug"
              },
              {
                "id": 140922631,
                "url": "https://finnhub.io/api/news?id=7b429b088d655c237aac8342e677ff2e6a0d4bbbe45d0f80f410066bf2a7a864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those ... The Portfolio That Pays All Your Car Repairs For Life",
                "category": "company",
                "datetime": 1784224058,
                "headline": "The Portfolio That Pays All Your Car Repairs For Life"
              },
              {
                "id": 140924331,
                "url": "https://finnhub.io/api/news?id=2cccc71304a92dbf83c35d1711fa335b36545f9818f085bb547e2a190d5858bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.",
                "category": "company",
                "datetime": 1784222460,
                "headline": "Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?"
              },
              {
                "id": 140922632,
                "url": "https://finnhub.io/api/news?id=7c29be2f94767e0c8e1e1ad8878c710d0617b7fa7550c65b0b37d527287ef6d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.",
                "category": "company",
                "datetime": 1784218260,
                "headline": "Sector ETFs to Win on Q2 Earnings Growth Potential"
              },
              {
                "id": 140924212,
                "url": "https://finnhub.io/api/news?id=f1a83df4a460a5536afadd68c6d8b67158a8073b9c8875f11b1e6d8dfa1c018b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268438699/image_2268438699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnsonâs strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ from Sell to Hold.",
                "category": "company",
                "datetime": 1784217215,
                "headline": "I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)"
              },
              {
                "id": 140920971,
                "url": "https://finnhub.io/api/news?id=6eac034c6914e1faa4d3597b25972ecf5df2fdb6a0f3aad2a0291a50be75e185",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.",
                "category": "company",
                "datetime": 1784216700,
                "headline": "Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion"
              },
              {
                "id": 140920972,
                "url": "https://finnhub.io/api/news?id=599fd74550f7b98d365d009af33a716949e9a10cb0c48e26cf5ef5e8637d71f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's (JNJ) Innovative Medicine segment momentum is building into 2027, with the compa",
                "category": "company",
                "datetime": 1784215796,
                "headline": "Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says"
              },
              {
                "id": 140920973,
                "url": "https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784212620,
                "headline": "Why Abbott Stock Is Having Its Best Day in 24 Years"
              },
              {
                "id": 140925253,
                "url": "https://finnhub.io/api/news?id=7b55a75cfcff35bfaea03818a622a465035efd6daf3d0186d0f34f068e6f793e",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Raymond James  analyst Jayson Bedford   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Outperform and raises the price target from $258 to $265.",
                "category": "company",
                "datetime": 1784211124,
                "headline": "Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265"
              },
              {
                "id": 140920962,
                "url": "https://finnhub.io/api/news?id=2cec22579047e245108d6c96f0282da91db225b322b2727f1dee0c8a8a992058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.",
                "category": "company",
                "datetime": 1784210761,
                "headline": "Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140920975,
                "url": "https://finnhub.io/api/news?id=7c8ef675a3c6fa5fb020f15ac8b4d391cda0c47a701fbe8e4984298f9b1e9e13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.",
                "category": "company",
                "datetime": 1784210400,
                "headline": "Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat"
              },
              {
                "id": 140920976,
                "url": "https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.",
                "category": "company",
                "datetime": 1784210345,
                "headline": "Why Abbott Stock Is Reimagining Its Future"
              },
              {
                "id": 140923118,
                "url": "https://finnhub.io/api/news?id=849660181dbdce21c5283300d80d1ffbd4882504fe8ef32a9722935ced89a103",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Konskie--Poland---September-07--2025-Uni.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "UnitedHealth&#39;s (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.",
                "category": "company",
                "datetime": 1784208257,
                "headline": "UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140925255,
                "url": "https://finnhub.io/api/news?id=a1e7a18b2666f804b907fee1ef3b62977722ec84865ee61dc95830e221a48894",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The reasons why RBC Capital Markets maintains its stock rating.",
                "category": "company",
                "datetime": 1784203897,
                "headline": "Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst"
              },
              {
                "id": 140919721,
                "url": "https://finnhub.io/api/news?id=6520635232f64f8347ba4e9dff3721065414e7b36bcf1950f94d2c6548cdc023",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 16, 2026--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all.",
                "category": "company",
                "datetime": 1784203860,
                "headline": "Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award"
              },
              {
                "id": 140919722,
                "url": "https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784203500,
                "headline": "Why Abbott Earnings Are Sending the Stock Higher"
              },
              {
                "id": 140919723,
                "url": "https://finnhub.io/api/news?id=de8e48f037f5c09136d811016bc9ddf198f5b74d438512b6dacad9fa099e2580",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "RAYNHAM, Mass., July 16, 2026--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.",
                "category": "company",
                "datetime": 1784203200,
                "headline": "DePuy Synthes Acquires Expanding Innovations™"
              },
              {
                "id": 140925256,
                "url": "https://finnhub.io/api/news?id=f6de372db2648d397e31f9942e51ccb26c3dd7374c1db33b16261b2fe74c1950",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "RBC Capital  analyst Shagun Singh   reiterates Johnson &amp; Johnson (NYSE:JNJ) with a Outperform and maintains $287 price target.",
                "category": "company",
                "datetime": 1784199879,
                "headline": "RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $287 Price Target"
              },
              {
                "id": 140925257,
                "url": "https://finnhub.io/api/news?id=c4ad69c879606e9a3f256389df43bbfaf5fa9660a189217a14842a88cab536dc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "A report on July 15, 2026 shows that Representative Thomas Kean from New Jersey sale stock in Alphabet (NASDAQ:GOOGL), valued between $26,012 and $215,000. According to the July filing, the transaction occurred on June",
                "category": "company",
                "datetime": 1784199622,
                "headline": "New Jersey Rep. Thomas Kean Sold Over $26K Worth of Alphabet Stock: Here’s What You Should Know"
              },
              {
                "id": 140925258,
                "url": "https://finnhub.io/api/news?id=8bf525878cd1213d29b7dccd45b7fb5e3eb5eb5f9f5d242f48df0f4e450f5507",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Overweight and raises the price target from $263 to $272.",
                "category": "company",
                "datetime": 1784199227,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272"
              },
              {
                "id": 140918830,
                "url": "https://finnhub.io/api/news?id=b8067d2e125f2fadd902082d475fcb21d24467c27a57848a9d67cfeb5786361c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income",
                "category": "company",
                "datetime": 1784197760,
                "headline": "The Portfolio Blueprint for Building $20,000 a Month in Dividend Income"
              },
              {
                "id": 140922157,
                "url": "https://finnhub.io/api/news?id=386c0b9c1c3d9557d90a82f0a6e027a81e4638d8b6d3f8ba2779826e7a8c42f5",
                "image": "https://image.cnbcfm.com/api/v1/image/108335965-17842089721784208970-47198742640-1080pnbcnews.jpg?v=1784208971&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1784194960,
                "headline": "Cramer’s Mad Dash: Johnson & Johnson"
              },
              {
                "id": 140925259,
                "url": "https://finnhub.io/api/news?id=8e8ff9972320acf9872e5c5f441d391a77a1bf0345ca3e918d5ba001518be010",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Overweight and raises the price target from $284 to $294.",
                "category": "company",
                "datetime": 1784193945,
                "headline": "Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294"
              },
              {
                "id": 140925260,
                "url": "https://finnhub.io/api/news?id=014de1ad8e4e545a4a3f02e2d375594a5f01a2ee6dea5eaa486ec601be65e351",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment.Expanding Innovations (EI) is a commercial-stage medical technology company",
                "category": "company",
                "datetime": 1784189685,
                "headline": "Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed"
              },
              {
                "id": 140918128,
                "url": "https://finnhub.io/api/news?id=f1402859602ca724ecf65893e4e4f5820ae506617dde2d10a6da383be625d1ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.",
                "category": "company",
                "datetime": 1784185971,
                "headline": "SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot"
              },
              {
                "id": 140916511,
                "url": "https://finnhub.io/api/news?id=e300002b4f43068403e89c192b53b22aa9c3919d052a002385f9017f92ad7e63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors didn't seem to think so after the company published it.",
                "category": "company",
                "datetime": 1784173167,
                "headline": "Is Johnson & Johnson a Buy After Its Latest Earnings Report?"
              },
              {
                "id": 140925261,
                "url": "https://finnhub.io/api/news?id=9f5bb9cd16e73156160575776209683ad183e46e25dbce73d4396b83af3a0168",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson &amp; Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to",
                "category": "company",
                "datetime": 1784166947,
                "headline": "Full Transcript: Johnson & Johnson Q2 2026 Earnings Call"
              },
              {
                "id": 140915424,
                "url": "https://finnhub.io/api/news?id=ab8372ecfee687d7abf018b7dce66c686ad6cd08febf8c3946af69c275a4cd45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.",
                "category": "company",
                "datetime": 1784150433,
                "headline": "Best Dividend Stocks to Buy for Dependable Dividend Growth"
              },
              {
                "id": 140914231,
                "url": "https://finnhub.io/api/news?id=f0632b36b806d3d0cb47d42432e310a59cbd17a7770bb0e0c19a70aac93b683c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.",
                "category": "company",
                "datetime": 1784150173,
                "headline": "Stock Market Today, July 15: Markets Rise on Cooler Inflation and Strong Earnings Start"
              },
              {
                "id": 140914232,
                "url": "https://finnhub.io/api/news?id=895aec057b4e3597ccabce3d9f9e117a9483c72895b973727e2a43ca3def1bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.",
                "category": "company",
                "datetime": 1784149262,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Raised ..."
              },
              {
                "id": 140912812,
                "url": "https://finnhub.io/api/news?id=d1dbf1f7ea79f9594822717b2881011dd0b4feefcaa01d1669fa51610f4a8da0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...",
                "category": "company",
                "datetime": 1784144040,
                "headline": "Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies"
              },
              {
                "id": 140912443,
                "url": "https://finnhub.io/api/news?id=6750508196e401c3e7147c7d16e101bbbf6a7f4a57e20206b50542adf6290ea5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1784142603,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140912813,
                "url": "https://finnhub.io/api/news?id=af3b9436f23bb6328aa43e6b3e1faf8d7dd198364bfa6e28cf7cd911df9289f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.",
                "category": "company",
                "datetime": 1784140381,
                "headline": "The Open Questions On ISRG Stock"
              },
              {
                "id": 140911280,
                "url": "https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State",
                "category": "company",
                "datetime": 1784137282,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140911186,
                "url": "https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.",
                "category": "company",
                "datetime": 1784136544,
                "headline": "Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"
              },
              {
                "id": 140911295,
                "url": "https://finnhub.io/api/news?id=4a791776ab37db358676e8be6b305d1ec3123f5214f8c1346ecc26403cfddb47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PayPal stock leads the S&P 500 while Sandisk is among the worst performers. Micron falls as chip stocks book significant losses.",
                "category": "company",
                "datetime": 1784134800,
                "headline": "Micron, PayPal, IBM, SpaceX, BlackRock, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140911296,
                "url": "https://finnhub.io/api/news?id=aee602b293e01bdae62f2d6674938ab67845e74bf45b3536a1bd3aa55fdad064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784134793,
                "headline": "J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others"
              },
              {
                "id": 140910530,
                "url": "https://finnhub.io/api/news?id=d3f52428a05de534ed0291c48948492f6aadc30b433f1701d5322f7b8d1fb595",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1784133603,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140911297,
                "url": "https://finnhub.io/api/news?id=787e4c2e5b8b34dbaa7ba190f36e70608d9c07c20239be6b5eb232e1e3172fd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.",
                "category": "company",
                "datetime": 1784132843,
                "headline": "Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King"
              },
              {
                "id": 140912735,
                "url": "https://finnhub.io/api/news?id=8a8b81142b9c7e4bb5438d07823228179787f4ff25c9657eff00ab62eca89eb8",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk -...",
                "category": "company",
                "datetime": 1784131079,
                "headline": "Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140909590,
                "url": "https://finnhub.io/api/news?id=88fcc255731ec69886d1295814f3e784ca3de4fa2badc7f414c8666b92de4cbb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led",
                "category": "company",
                "datetime": 1784130649,
                "headline": "Top Midday Stories: PayPal Reportedly Gets Acquisition Offer From Stripe, Advent; ASML Misses Q2 EPS, Sales Estimates, Lifts Outlook"
              },
              {
                "id": 140909591,
                "url": "https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s  second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed.  J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”",
                "category": "company",
                "datetime": 1784128500,
                "headline": "Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"
              },
              {
                "id": 140909592,
                "url": "https://finnhub.io/api/news?id=007d15c9cf8e2ff35d41bbed5ecbb0afd386fd8bd943e6f92ab6307e2cfd496b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.",
                "category": "company",
                "datetime": 1784128454,
                "headline": "J&J raises FY26 outlook following positive Q2"
              },
              {
                "id": 140909593,
                "url": "https://finnhub.io/api/news?id=d077f71ff7fbd751fd25832e105b62d8886c21a60d7ea11acb36a69a781e58a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...",
                "category": "company",
                "datetime": 1784128337,
                "headline": "Johnson & Johnson (JNJ) Tops $100 Billion In Annual Revenue For The First Time"
              },
              {
                "id": 140911298,
                "url": "https://finnhub.io/api/news?id=68daeb1521e8e1d59a5f8a5092dccf50dc34cd5e70838a036646bc5876a08361",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Producer Inflation Cools in June",
                "category": "company",
                "datetime": 1784127300,
                "headline": "Producer Inflation Cools in June"
              },
              {
                "id": 140909594,
                "url": "https://finnhub.io/api/news?id=ec340f83e790a33d8578eaabbe70e16e33fdc6e6b4e59590d771d0a8d3a886df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.",
                "category": "company",
                "datetime": 1784127000,
                "headline": "J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised"
              },
              {
                "id": 140909595,
                "url": "https://finnhub.io/api/news?id=734ecd32e0b0bb076cabb9c846905c77fbf49fb3332c67befbe8f37a58387e50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?",
                "category": "company",
                "datetime": 1784126640,
                "headline": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?"
              },
              {
                "id": 140909596,
                "url": "https://finnhub.io/api/news?id=ccd29988ec70f94492a68a9bfcc87fe887cf810dd56988d4d935a873da283740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...",
                "category": "company",
                "datetime": 1784126520,
                "headline": "Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance"
              },
              {
                "id": 140909597,
                "url": "https://finnhub.io/api/news?id=d56e980eea938f5552ae174918377651845cf671b35640abd87fa2e22973148a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.",
                "category": "company",
                "datetime": 1784125920,
                "headline": "PPI Slides in June on Lower Oil Prices, Q2 Results Continue"
              },
              {
                "id": 140909598,
                "url": "https://finnhub.io/api/news?id=7dab795452149bd3414880bc74c107b79159251545e9f97ed6871bfed9ab6e77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "FEATURE  Stocks were rising Wednesday, building on recent gains, as a cooler-than-expected producer price index print boosted investor sentiment. Wall Street also assessed another batch of quarterly earnings reports with chip-machine supplier ASML  offering an encouraging read on the artificial-intelligence trade.",
                "category": "company",
                "datetime": 1784125260,
                "headline": "Intel, Marvell, PayPal, IBM, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140909599,
                "url": "https://finnhub.io/api/news?id=02bc3408b143d0b0d2c85943c9e5093fa90ca7d4d087bd71c3ae77d3510fbd3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.",
                "category": "company",
                "datetime": 1784124278,
                "headline": "Johnson & Johnson Q2 Earnings Call Highlights"
              },
              {
                "id": 140909600,
                "url": "https://finnhub.io/api/news?id=1d6738c6d9a78ffd93f1b782aa95276bb3cb97c56d5097551f9eecc53a118792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.",
                "category": "company",
                "datetime": 1784124027,
                "headline": "Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner"
              },
              {
                "id": 140908252,
                "url": "https://finnhub.io/api/news?id=e4f75f3b4d5bc9653feb149741bd86881e2f09000474bc9c816c18cdfe4b02f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect",
                "category": "company",
                "datetime": 1784123441,
                "headline": "Johnson & Johnson Lifts Full-Year Outlook Following Second-Quarter Beat"
              },
              {
                "id": 140908253,
                "url": "https://finnhub.io/api/news?id=f8e971a5a6caad75bc55b5177e35e9617e2d8fa27564a81e9ef8f0b6a46646a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]",
                "category": "company",
                "datetime": 1784123188,
                "headline": "Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment"
              },
              {
                "id": 140909601,
                "url": "https://finnhub.io/api/news?id=b5061df4902a47af987466427333da6c9fe92bdb416e459fa06f1c832924ea69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1784122204,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 140908133,
                "url": "https://finnhub.io/api/news?id=480ecd1efdac3a227829eb7883cc5a86f40c88e0b34b3e5bcfe8c909920a0c06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1784120409,
                "headline": "Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"
              },
              {
                "id": 140908255,
                "url": "https://finnhub.io/api/news?id=cc258d3da9ae53838311586792668a5eb94f9b6a67e133c42920618179502504",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784119721,
                "headline": "Healthcare Bellwether J&J Beats And Raises, But Shares Dip"
              },
              {
                "id": 140910451,
                "url": "https://finnhub.io/api/news?id=8adf3a174d992a7822510053eb8715506de936528378933346c11d59ad88c317",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1159967002/image_1159967002.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Tech analyst Dan Ives, known for his bullish calls on stocks like Apple (AAPL) and AI names announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank.",
                "category": "company",
                "datetime": 1784118720,
                "headline": "Wall Street Lunch: Dan Ives Teams Up With Yorkville Securities To Launch Merchant Bank"
              },
              {
                "id": 140908256,
                "url": "https://finnhub.io/api/news?id=96eb4c84d427590062d9d4cf07c341c0c76f5da3bf6ed65246a738b27ba4dff8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "News of the day for July 15, 2026",
                "category": "company",
                "datetime": 1784117187,
                "headline": "5 Things to Know Before the Stock Market Opens on Wednesday"
              },
              {
                "id": 140908257,
                "url": "https://finnhub.io/api/news?id=dffcbd487144d4902ca503dee639eaaf4fee28eafeab18706d3f53e33252bd4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US equity futures were edging higher pre-bell Wednesday as traders considered the latest inflation d",
                "category": "company",
                "datetime": 1784117178,
                "headline": "US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions"
              },
              {
                "id": 140908248,
                "url": "https://finnhub.io/api/news?id=edd8af44fdbc11a7818dc1e61ec4669942ac8cd0ad4a1001892de1ac2f9b1a85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.",
                "category": "company",
                "datetime": 1784117108,
                "headline": "Dow Jones Futures: Techs Rise, Oil Hits $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"
              },
              {
                "id": 140908259,
                "url": "https://finnhub.io/api/news?id=4bd6543c66cee9ca607ffacfe474a01c59fd8ff61427054401f77309c9bfbbee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year",
                "category": "company",
                "datetime": 1784116945,
                "headline": "The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year"
              },
              {
                "id": 140908260,
                "url": "https://finnhub.io/api/news?id=25d2f4579b69c5e41cd7ab96a5efc1ac5cbc9866e68f0703118c2c0ea471ad90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint",
                "category": "company",
                "datetime": 1784116917,
                "headline": "Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength"
              },
              {
                "id": 140907340,
                "url": "https://finnhub.io/api/news?id=a4991ce4f683f91b710365cca22adbf8237f8b0e8a06f4416b51ca7ee2a6bae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.",
                "category": "company",
                "datetime": 1784115687,
                "headline": "Dow Jones Futures: Oil Prices Hit $80 On Iran News, ASML, Morgan Stanley Lead Earnings Movers"
              },
              {
                "id": 140908261,
                "url": "https://finnhub.io/api/news?id=2a1b2e7c2e336f9a72b568b5ac722ab04c6ed98c7f6cdafa9f706f35418c5d37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson  raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara.  The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.",
                "category": "company",
                "datetime": 1784115480,
                "headline": "Why Johnson & Johnson Stock Is Falling Even After a Guidance Hike"
              },
              {
                "id": 140909365,
                "url": "https://finnhub.io/api/news?id=76a3181bef3b2c7150e33ad598c8a16d2c5b4eb03982ca724028760ddb0d572e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266159678/image_2266159678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson Q2 2026 results: 6.6% revenue growth, Pharma/MedTech strength, and dividend stability. Click for this JNJ earnings update.",
                "category": "company",
                "datetime": 1784115253,
                "headline": "Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street"
              },
              {
                "id": 140908262,
                "url": "https://finnhub.io/api/news?id=a3c02aed2f2d9e07701c9501ce2b08e8169b8f19ffb57cb4a98f015f765f168f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784115002,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 140907559,
                "url": "https://finnhub.io/api/news?id=1fcb7f84b47d3bc10563f5ccefe5eebb163514c3e049267d25c046760da9f4a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.",
                "category": "company",
                "datetime": 1784114820,
                "headline": "Intel, Johnson & Johnson, ASML, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140907215,
                "url": "https://finnhub.io/api/news?id=572fb61f26bb74b899035732346e05f98565a6037204b53e0381a10ee1e45214",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "J&J reported Q2 earnings in line with estimates, raised full-year guidance for sales and EPS, yet saw muted market reaction with stock down ~1.9% pre-market.",
                "category": "company",
                "datetime": 1784114488,
                "headline": "Johnson & Johnson (NYSE:JNJ) Raises Full-Year Guidance After In-Line Q2 Results"
              },
              {
                "id": 140907439,
                "url": "https://finnhub.io/api/news?id=76dbabe7c9bad302caf7f990b149c1d0f961308d4c92e74ca73b24759b95cb82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.",
                "category": "company",
                "datetime": 1784114094,
                "headline": "Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)"
              },
              {
                "id": 140907440,
                "url": "https://finnhub.io/api/news?id=d4fc0e49f6e84d53b084291f70ad0fbf1c7a69ea8a5e79f1be0d2c5663bcdcba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.",
                "category": "company",
                "datetime": 1784113435,
                "headline": "Johnson & Johnson beats estimates but shares dip"
              },
              {
                "id": 140907441,
                "url": "https://finnhub.io/api/news?id=ba0258ea77d7da09c8ab76bbdbc2029b8a4ec44098d830ba03fc4e837e4aab91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson will release its second-quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus...",
                "category": "company",
                "datetime": 1784112366,
                "headline": "How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings"
              },
              {
                "id": 140907442,
                "url": "https://finnhub.io/api/news?id=d1efded5187965b2a59a2176420140c6e70982a359b4b270f05f5ecdfea4f944",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026.",
                "category": "company",
                "datetime": 1784111100,
                "headline": "Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026"
              },
              {
                "id": 140907443,
                "url": "https://finnhub.io/api/news?id=c49fb7ab1c6a5837fa280079290342e09b697867de272310a858fd2028764223",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor",
                "category": "company",
                "datetime": 1784110920,
                "headline": "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026"
              },
              {
                "id": 140907444,
                "url": "https://finnhub.io/api/news?id=4f08eae507e1193ecb087dcc13a87d4db5cffa3d7fa6b20ed072017e691b054f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., July 15, 2026--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. \"Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,\" said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. \"With raised guidance and quarterly sales surpassin",
                "category": "company",
                "datetime": 1784110800,
                "headline": "Johnson & Johnson reports Q2 2026 results, raises 2026 outlook"
              },
              {
                "id": 140907445,
                "url": "https://finnhub.io/api/news?id=845f41dc98196ae4fdb92ce50ceddd355048dd46df86616dbd3b41d7db42e9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eight thousand dollars a month is the kind of retirement income target that looks simple until the yield math starts moving underneath it. It translates to $96,000 a year, but the portfolio needed to produce that income can vary by well over $1 million depending on whether the investor accepts a 3.5% yield, a 6% ... What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield",
                "category": "company",
                "datetime": 1784110629,
                "headline": "What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield"
              },
              {
                "id": 140907446,
                "url": "https://finnhub.io/api/news?id=2d02d5cf0d75ca0cae255786ac3585d494c1f5d01af68e5d8c01eab28b11bce2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data.  Nasdaq 100 futures added 0.4%.  Dow Jones Industrial Average futures rose 81 points, or 0.2%.",
                "category": "company",
                "datetime": 1784110182,
                "headline": "Stock Futures Jump. Market Rally Gathers Pace as Earnings Season Ramps Up."
              },
              {
                "id": 140911822,
                "url": "https://finnhub.io/api/news?id=fa17715f1b72478afab6a288d6534679bb604cbc46e9c70eb3af7c4aabfe45b6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson &amp; Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.",
                "category": "company",
                "datetime": 1784107911,
                "headline": "Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook"
              },
              {
                "id": 140910786,
                "url": "https://finnhub.io/api/news?id=c4a2d146e21fb7daa47e67c402fb3a6be0643ebcff00aa0e2b61cce8bc1a91ef",
                "image": "https://image.cnbcfm.com/api/v1/image/108260658-17701229642026-02-03t122144z_241610661_rc2bejauv8r4_rtrmadp_0_paypal-results.jpeg?v=1770122981&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1784100829,
                "headline": "Stocks making the biggest moves premarket: BlackRock, PayPal, ASML, Morgan Stanley & more"
              },
              {
                "id": 140910787,
                "url": "https://finnhub.io/api/news?id=0a6f3fe8f6935b5badfdfb4b9e31644dc77a38f0ee71f38c650e4c414cc302f2",
                "image": "https://image.cnbcfm.com/api/v1/image/108335230-4ED1-MC-071526-Vamil.jpg?v=1784114956&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Vamil Divan, Senior Biopharma Research Analyst at Guggenheim Securities, said Johnson & Johnson has moved past patent losses and is benefiting from a strong pipeline of new products driving future growth.",
                "category": "company",
                "datetime": 1784100565,
                "headline": "Vamil Divan: We are looking for accelerating growth into 2027"
              },
              {
                "id": 140908853,
                "url": "https://finnhub.io/api/news?id=89e4833a9fa20ccd77cb554da88c61423a07541323a70d40a9fcab10af32f087",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Companies Reporting Before The Bell\n• VCI Global (NASDAQ:VCIG) is estimated to report earnings for its Fiscal Year 2025. \n• PNC Financial Services Gr (NYSE:PNC) is projected to report quarterly earnings at $4.43 per",
                "category": "company",
                "datetime": 1784099470,
                "headline": "Earnings Scheduled For July 15, 2026"
              },
              {
                "id": 140911824,
                "url": "https://finnhub.io/api/news?id=11a8881829fa4914e6ee2fc5098e938c170e5ed482291fd038de8dbfa2c660f6",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": " Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the",
                "category": "company",
                "datetime": 1784096758,
                "headline": "Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoY"
              },
              {
                "id": 140911825,
                "url": "https://finnhub.io/api/news?id=03d694a3a8b38f252ce1e205d13eeb0463233f273a356f676bb5de03344a8c5b",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson &amp; Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 analyst estimate. Raises FY2026 sales outlook from $100.300 billion-$101.300 billion to $100.800",
                "category": "company",
                "datetime": 1784096536,
                "headline": "Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.45-$11.65 to $11.60-$11.75 vs $11.59 Est; Raises FY2026 Sales Guidance from $100.300B-$101.300B to $100.800B-$101.400B vs $101.022B Est"
              },
              {
                "id": 140911826,
                "url": "https://finnhub.io/api/news?id=7ba5559f31c8d34a08ffe13e149cac885181af43fa70368300ee8346b21d1074",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "]",
                "category": "company",
                "datetime": 1784096449,
                "headline": "Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate"
              },
              {
                "id": 140908855,
                "url": "https://finnhub.io/api/news?id=0bd9ec8d7935ec4e27c1dc576e933c71816c604d8f0f286f1acb887ea775203b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/People-Silhouettes-On-American-Stock-Mar.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "July 15, 2026: Polymarket traders expect the S&amp;P 500 to open higher on Wednesday after cooler inflation sharply reduced July Fed hike expectations.",
                "category": "company",
                "datetime": 1784089520,
                "headline": "Stock Market: Will S&P 500 Open Up or Down Today?"
              },
              {
                "id": 140910605,
                "url": "https://finnhub.io/api/news?id=cc8b2768dae29ccd6206162d2aecd5c2e53559f0e95747d25b043050577d0301",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "CNN Money Fear and Greed index improved, but remained in Fear zone. U.S. stocks mostly higher on inflation data.",
                "category": "company",
                "datetime": 1784085469,
                "headline": "Nasdaq Gains Over 200 Points Following Inflation Report: Investor Sentiment Improves, Greed Index Remains In ‘Fear' Zone"
              },
              {
                "id": 140910606,
                "url": "https://finnhub.io/api/news?id=7931fb5218a4714b2f3aead3ebddba4767322b6b545a5af35cbc89c7d60d1f5a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/London--United-Kingdom---February-26--20.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley, Pentair, Johnson &amp; Johnson expected to release earnings, ASML posts strong results, Progressive to report",
                "category": "company",
                "datetime": 1784082564,
                "headline": "Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday"
              },
              {
                "id": 140904169,
                "url": "https://finnhub.io/api/news?id=767d2ade90ef611607c1a4bca821949c13486a341ca98a855029fee95d289c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.",
                "category": "company",
                "datetime": 1784072870,
                "headline": "Dow Jones Futures Rise; Goldman, CrowdStrike Jump, But AI Stocks Need To Do This"
              },
              {
                "id": 140902827,
                "url": "https://finnhub.io/api/news?id=1f6b453f31d34dccef7a765a871c263304660a1877335a34668902c89bd77538",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.",
                "category": "company",
                "datetime": 1784062760,
                "headline": "Dow Jones Futures: Goldman, CrowdStrike Jump, AI Stocks Need To Do This; ASML, Morgan Stanley Due"
              },
              {
                "id": 140910779,
                "url": "https://finnhub.io/api/news?id=e36c920525aaa0874fb55e565da7f7840590e65eeb85912374ef661a4127c708",
                "image": "https://image.cnbcfm.com/api/v1/image/108324283-17818184352026-06-18t212644z_311932191_rc2kwlaz3beo_rtrmadp_0_usa-stocks.jpeg?v=1781818551&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Stocks closed higher on Tuesday, helped by signs of easing inflation, which boosted investor hopes that the Federal Reserve can hold off on rate hikes for the moment.",
                "category": "company",
                "datetime": 1784056328,
                "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140901110,
                "url": "https://finnhub.io/api/news?id=a418695849289d29baabb02fccad0cc1323fa81f759a05f46d8ec554e1e50864",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1784056204,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140901466,
                "url": "https://finnhub.io/api/news?id=3b28393a5831026f9ac3732237381ea888082eee864a93bb498cf961a423a22f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.",
                "category": "company",
                "datetime": 1784052407,
                "headline": "The Paid-To-Hold Play On ISRG Stock: A 12% Income"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140902248,
                "url": "https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.",
                "category": "company",
                "datetime": 1784047680,
                "headline": "A Fresh Look At Syndax Pharmaceuticals"
              },
              {
                "id": 140899749,
                "url": "https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.",
                "category": "company",
                "datetime": 1784046620,
                "headline": "This Healthcare Giant Still Checks Every Box for Long-Term Investors"
              },
              {
                "id": 140902323,
                "url": "https://finnhub.io/api/news?id=328fd13fc461312f4abaa2aa4d14fd146e994b9dd8b50474f58fe81e55a60d67",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Marketplace-Enrollment-Declines.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Earnings for ASML, Progressive, and BNY Mellon are coming with implied moves of 3.89%, 3.89%, and 4.14% respectively, reflecting market expectations for post-print repricing risk.",
                "category": "company",
                "datetime": 1784046094,
                "headline": "ASML Could Swing 7.5% After Earnings on Wednesday"
              },
              {
                "id": 140899750,
                "url": "https://finnhub.io/api/news?id=804eb2632a3ad3085591338bd6e8d9f028e77cc907f15421b301c5d84b07d50e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $1.4 million nest egg is far above the typical U.S. retirement account balance, but the check it writes each month depends entirely on how the assets are arranged. At a 3.5% yield, the portfolio produces $49,000 a year. At a 10% yield, it produces $140,000. The difference looks simple on a spreadsheet, but it ... A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets",
                "category": "company",
                "datetime": 1784045547,
                "headline": "A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140898076,
                "url": "https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.",
                "category": "company",
                "datetime": 1784039400,
                "headline": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"
              },
              {
                "id": 140898077,
                "url": "https://finnhub.io/api/news?id=bfd8f460c4d367b16145d1b4ffd79af32bdd28c9d051cfdbb4030e02693a8e59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock has returned 77.8% over the past five years and now sits at a point where a Discounted Cash Flow (DCF) intrinsic value estimate suggests meaningful upside while the broader valuation checks look much less generous. A 77.8% five year return sets the context for assessing whether today’s price still leaves enough potential reward for the risk involved. Progress in oncology and autoimmune drugs can support long term cash flow expectations, while ongoing talc related...",
                "category": "company",
                "datetime": 1784038477,
                "headline": "Johnson & Johnson (JNJ) Stock May Be Reasonable After Talc Verdict Ruling"
              },
              {
                "id": 140898078,
                "url": "https://finnhub.io/api/news?id=662432f9abe149819b5e3060f6fa533bf33f671aa0c5610830a23d64bd69986f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "San Francisco makes passive income math unforgiving. SmartAsset’s 2026 comfort-salary study estimates that a single adult needs about $134,950 in pretax income to live comfortably in the city, among the highest figures in the country. Turning that paycheck into dividend income is not just a yield exercise. The yield an investor reaches for changes both ... A Dividend Portfolio That Can Cover the Cost of Living in San Francisco",
                "category": "company",
                "datetime": 1784037813,
                "headline": "A Dividend Portfolio That Can Cover the Cost of Living in San Francisco"
              },
              {
                "id": 140898041,
                "url": "https://finnhub.io/api/news?id=f81b5704db160b35b4aa4e9fe38b791120b54b59fe0684be4ae1b6f05f59f94e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.",
                "category": "company",
                "datetime": 1784037240,
                "headline": "Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge"
              },
              {
                "id": 140896860,
                "url": "https://finnhub.io/api/news?id=69cac81872a917b82ac0a4526f38f4b08928a2ae81ab419989126f3ac804ca95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.",
                "category": "company",
                "datetime": 1784033543,
                "headline": "ISRG Stock: What Does Its Valuation Imply?"
              },
              {
                "id": 140896861,
                "url": "https://finnhub.io/api/news?id=50ca3d5ebf3ad6a5d9c62186736be99edd52483da4c3f0093b6e6925bb8eca50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A series of big bank results kicked off the second quarter earnings season on Tuesday.",
                "category": "company",
                "datetime": 1784030838,
                "headline": "Earnings live: Wall Street bank stocks mixed despite profit haul"
              },
              {
                "id": 140899751,
                "url": "https://finnhub.io/api/news?id=d1aa5a730c62073f57143bd0a22d3a9540c6140220402a1e4e9ae24f822d7381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.",
                "category": "company",
                "datetime": 1784030400,
                "headline": "Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill"
              },
              {
                "id": 140903560,
                "url": "https://finnhub.io/api/news?id=4de721486aee9a85d315832d79e4a7091464b812938b3bfd4f046dad27e0b9b1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson &amp; Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead.",
                "category": "company",
                "datetime": 1784030120,
                "headline": "Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’"
              },
              {
                "id": 140895304,
                "url": "https://finnhub.io/api/news?id=157f7c5da8ff0a5e4f2a825c575e945d68e2085c942ec86685abf546d23b7c5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Opportunities include integrating cardio-renal strategies, aligning therapies with real-world evidence, leveraging site-of-care economics, and enhancing supply resilience amid tariff influences. Late Stage Chronic Kidney Disease Therapeutics Market Late Stage Chronic Kidney Disease Therapeutics Market Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The \"Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering.The Late Stage",
                "category": "company",
                "datetime": 1784016960,
                "headline": "Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape"
              },
              {
                "id": 140895245,
                "url": "https://finnhub.io/api/news?id=083d10d3df50abc007cf7a68b661f56bc381dc0eef52cb3dc0a00a03b28e8bf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The dividend looks secure. The share price is the harder call.",
                "category": "company",
                "datetime": 1784016060,
                "headline": "This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?"
              },
              {
                "id": 140892514,
                "url": "https://finnhub.io/api/news?id=b85633b633036327b86c0744adb5fccb38fa08d2530290494286e8859a41fa44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "After hitting fresh all-time highs last week, investors are turning their attention to JNJ's Q2 report, which is scheduled for Wednesday, July 15, before the opening bell.",
                "category": "company",
                "datetime": 1783979400,
                "headline": "Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?"
              },
              {
                "id": 140891291,
                "url": "https://finnhub.io/api/news?id=70d70f99824f8bcd6503316a221bd6d1b30ecdf59e8dfb17ad8bd115267f3c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with market moves at the end of the day.) Equities on Wall Street fell Monday, snapping",
                "category": "company",
                "datetime": 1783975302,
                "headline": "Update: Nasdaq Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran Tensions"
              },
              {
                "id": 140889992,
                "url": "https://finnhub.io/api/news?id=5c60b34df24e7ae144e94c72b25a9ce7b052938d9182985218906432e122789c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Social Security benefits come with inflation protection, but the tax formula attached to those benefits does not. For retirees with pensions, IRA withdrawals, taxable investment income, or municipal bond interest, a larger benefit can quietly mean a larger federal tax bill. The result is a tax rule from the 1980s that reaches more retirees every ... How Much of Your Social Security Will You Actually Keep After Taxes?",
                "category": "company",
                "datetime": 1783967289,
                "headline": "How Much of Your Social Security Will You Actually Keep After Taxes?"
              },
              {
                "id": 140889066,
                "url": "https://finnhub.io/api/news?id=6c4da60e3f458aee87f8080c7136136deca2a95a5b07afe2220895b88f67aaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US benchmark equity indexes were lower intraday, while oil prices jumped as President Donald Trump s",
                "category": "company",
                "datetime": 1783966889,
                "headline": "Equities Fall Intraday, Oil Soars as Trump Reinstates Iranian Shipping Blockade in Hormuz"
              },
              {
                "id": 140888392,
                "url": "https://finnhub.io/api/news?id=39384362546aba63a4bdfcb9862c1f6ebc3805d8f428319157998c59d8b43bb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the",
                "category": "company",
                "datetime": 1783962000,
                "headline": "Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight"
              },
              {
                "id": 140888393,
                "url": "https://finnhub.io/api/news?id=be7524a6a82f777e2943b1fa2d1bdb5a220852a4ed4bc08e478968a3127e2c97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.",
                "category": "company",
                "datetime": 1783960680,
                "headline": "Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?"
              },
              {
                "id": 140888394,
                "url": "https://finnhub.io/api/news?id=4d161bbf2ccc3f00b9c0b75fa9af0cd27d948429dd59ab9b9a11b4fe0fb3cd40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Both Johnson and Johnson and Coca-Cola just beat earnings and both are pulling in capital fleeing tech, but only one of them earns its premium valuation in a world where pricing tailwinds can reverse overnight.",
                "category": "company",
                "datetime": 1783959779,
                "headline": "JNJ Vs. KO: Which Dividend Stock Is The Better Buy?"
              },
              {
                "id": 140888395,
                "url": "https://finnhub.io/api/news?id=d50a547fa1d3601a3e58d3875738fe9d6e0ce21f3732b749f55851854f20a1a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Bloomberg) -- A federal appeals court revived lawsuits that claim Kenvue Inc. hid alleged risks that Tylenol could cause autism in children whose mothers took the over-the-counter pain medication while pregnant, a controversy that’s roiled the medical community.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Embraces Australian Retirement System Backed by Larry FinkHormuz Route Open Despite Iran Declaration, Maritime Group SaysOpenAI Engineer’s ‘LOL’ Momen",
                "category": "company",
                "datetime": 1783956006,
                "headline": "Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says"
              },
              {
                "id": 140886837,
                "url": "https://finnhub.io/api/news?id=a694c9a0e95f8d145f8e0632c815b0a0d2b5682d9beaca14a3e4a670f35a44a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ is set to report second-quarter results on July 15 as investors weigh strong growth drivers, new launches and patent headwinds shaping its long-term outlook.",
                "category": "company",
                "datetime": 1783953780,
                "headline": "Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?"
              },
              {
                "id": 140897508,
                "url": "https://finnhub.io/api/news?id=782912995a7134b2856f5498ba5653434f29eb8380d197246adc2164cd91a950",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "TD Cowen  analyst Michael Nedelcovych   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Buy and raises the price target from $250 to $300.",
                "category": "company",
                "datetime": 1783951773,
                "headline": "TD Cowen Maintains Buy on Johnson & Johnson, Raises Price Target to $300"
              },
              {
                "id": 140885789,
                "url": "https://finnhub.io/api/news?id=20ff394bd4bf79df2f0b55793c6a2702ed9a9f3f019a739fe68f85e68c88bc15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "An $80,000 salary is not the same as $80,000 of spendable income. Federal withholding, FICA taxes, state income taxes where they apply, and retirement contributions all reduce the number that actually reaches checking. For a single filer in a no-income-tax state, 2026 take-home pay on an $80,000 salary would be about $65,100 before retirement contributions, ... Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account",
                "category": "company",
                "datetime": 1783950887,
                "headline": "Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account"
              },
              {
                "id": 140888226,
                "url": "https://finnhub.io/api/news?id=2fc7e2002ab8e39cabb3974c06cad1fde6ceec9d2584a7770aa6b20f081d01e9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184220601/image_2184220601.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Build a resilient dividend income portfolio with quality stocks & ETFs: 3.75% yield, low payout ratios, low beta, and defensive sector focus. Here's what investors need to consider.",
                "category": "company",
                "datetime": 1783950349,
                "headline": "How To Build A $50,000 Dividend Portfolio In Today's Market"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140885760,
                "url": "https://finnhub.io/api/news?id=734257c65af1e4a45e054a81f546b19b506aa280c7ec495b4ea647dd16f3139c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with recent oil price movement, world markets' overview and corporate stock movements.)",
                "category": "company",
                "datetime": 1783946963,
                "headline": "Update: US Equity Futures Drop Pre-Bell as Iran Says Strait of Hormuz Closed Once Again, Oil Prices Jump"
              },
              {
                "id": 140885670,
                "url": "https://finnhub.io/api/news?id=550549e70d592f1616b71600c3535938a693ddd64a3aa9d85eaf5bda54146da8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15",
                "category": "company",
                "datetime": 1783945817,
                "headline": "The Real Case for Buying Johnson & Johnson (JNJ) Before July 15"
              },
              {
                "id": 140885778,
                "url": "https://finnhub.io/api/news?id=f8ad9fe1cdc29ab2e704c003f47d60e87729cfe29b01ce96258361c5da2e9bee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US equity futures were lower pre-bell Monday as hostilities continued to re-escalate in the Middle E",
                "category": "company",
                "datetime": 1783943964,
                "headline": "US Equity Futures Drop Pre-Bell as Iran Says Strait of Hormuz Closed Once Again, Oil Prices Jump"
              },
              {
                "id": 140885766,
                "url": "https://finnhub.io/api/news?id=db128b9932184c522216eea679afd213facf746d65ac46821262b27fe9249c59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The benchmark US equity measures were pointing lower before the opening bell Monday amid rising tens",
                "category": "company",
                "datetime": 1783943685,
                "headline": "Equity Futures Down Amid Middle East Tensions; Key Earnings on Deck"
              },
              {
                "id": 140884988,
                "url": "https://finnhub.io/api/news?id=7ba6010589532f31957cbc01d14660bf4b1be15d94fec0bd8703f6a17977156b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A legal career can eventually deliver a six-figure income, but the path is rarely passive. The median annual wage for lawyers was $151,160 in May 2024, and attorneys in higher-paid roles can clear $200,000 or more. The tradeoff is years of training, tuition, billable hours, and pressure that does not disappear when the workday ends. ... This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School",
                "category": "company",
                "datetime": 1783939504,
                "headline": "This Portfolio Lets You Earn More Than a Lawyer… Without Going to Law School"
              },
              {
                "id": 140897509,
                "url": "https://finnhub.io/api/news?id=5e5469c3d9daad982ecb7d2d147a6bd4ac93cffa780187afc15c3d25dc947572",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "RBC Capital  analyst Shagun Singh   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Outperform and raises the price target from $265 to $287.",
                "category": "company",
                "datetime": 1783938127,
                "headline": "RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $287"
              },
              {
                "id": 140885533,
                "url": "https://finnhub.io/api/news?id=41b2eb0f4e7cbea05dd165e84c0a30786986d7c1dfbfbbd4b7e79dd8b033872a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248883890/image_2248883890.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Virtus Equity & Convertible Income Fund (NIE) yields 8.68% with equities/convertibles.",
                "category": "company",
                "datetime": 1783935107,
                "headline": "NIE: High Tech Exposure Poses Risks For This High Yielding CEF"
              },
              {
                "id": 140884402,
                "url": "https://finnhub.io/api/news?id=7e019bdbd696e4fd6d39936b0e69a10c9989463cd9926bd77fb582cf144e20c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The math on replacing $60,000 of annual income looks simple until you ask a different question. At a 3.5% yield, you need roughly $1.7 million. At 6%, you need about $1 million. At 12%, you need around $500,000. Three tiers, three price tags, and three very different risk profiles. The trap is treating that choice ... The Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000",
                "category": "company",
                "datetime": 1783933237,
                "headline": "The Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000"
              },
              {
                "id": 140886499,
                "url": "https://finnhub.io/api/news?id=fe2cc42d718bb0ede68b078e17a8e90e9c2cdfed4ed647b4dee06d264e76c81d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Earnings-Season-Written-In-Search-Bar-Wi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "TSMC, JPMorgan, ASML, Netflix and more report earnings next week. See the options-implied moves, market caps and billions in market value at stake.",
                "category": "company",
                "datetime": 1783930923,
                "headline": "TSMC Could Swing $150 Billion as Options Market Prices Big Moves for This Week’s Earnings"
              },
              {
                "id": 140884397,
                "url": "https://finnhub.io/api/news?id=745ed4782ce5c544431b119b8ca7a5eb65da0c9a04bb5c6fd8fe63dd1eb87ce9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JPMorgan, Wells Fargo, Citigroup and Bank of America have been highlighted in this Earnings Preview article.",
                "category": "company",
                "datetime": 1783926540,
                "headline": "JPMorgan, Wells Fargo, Citigroup and Bank of America  are part of Zacks Earnings Preview"
              },
              {
                "id": 140879806,
                "url": "https://finnhub.io/api/news?id=907e2e24801890e310d3f807ab81b4d98bbe1b8da7227d4e168237c53a893e67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Ten years ago, a buyer of Lowe’s (NYSE:LOW) could pick up shares near $66 and collect a quarterly dividend that rose to $0.35 later in 2016. Today, the same share pays $1.25 per quarter, and the stock recently traded near $222. A decade of raises turned a modest-yield holding into a much larger paycheck on ... The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year",
                "category": "company",
                "datetime": 1783883349,
                "headline": "The Dividend Growth Approach That Builds Bigger Paychecks Every Single Year"
              },
              {
                "id": 140879807,
                "url": "https://finnhub.io/api/news?id=be8a7e25bd648b9d168672c8ccdb1dcebb365f3c11f3d51c03c27b2ed0f9dbe1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Big banks kick off earnings season this week, which will also bring reports from GE Aerospace, Netflix, and Taiwan Semi. In economic news, we’ll get the consumer and producer price indexes, and retail sales data.",
                "category": "company",
                "datetime": 1783879200,
                "headline": "Inflation, Bank of America, Wells Fargo, Goldman, ASML, J&J, and More to Watch This Week"
              },
              {
                "id": 140881859,
                "url": "https://finnhub.io/api/news?id=0bc2f69608268dd739dda977092c9c1f8e92d222919a3d60f150f4f1cb6a0c29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Markets face one of the year's most important weeks as Federal Reserve Chair Kevin Warsh delivers his inaugural semi-annual monetary policy testimony before Congress on July 14 and 15.",
                "category": "company",
                "datetime": 1783875602,
                "headline": "Huge Earnings, Inflation Data and Other Key Things to Watch this Week"
              },
              {
                "id": 140877858,
                "url": "https://finnhub.io/api/news?id=a153814ff186a2d67772186ad8519b068e929e095c5a45e757eeba152fcf1d92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two retirees can both pull $100,000 from $2 million income portfolios and still land in very different places after tax. If one stream is mostly qualified dividends and the other is mostly ordinary income, the first retiree may keep about $79,000 after a 15% federal qualified-dividend rate and 6% state tax. The second may keep ... Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes",
                "category": "company",
                "datetime": 1783869843,
                "headline": "Your Dividend Yield Isn’t Your Income: What You Really Keep After Taxes"
              },
              {
                "id": 140885726,
                "url": "https://finnhub.io/api/news?id=f5141d0e31451505d4140e7457dd08d2f99e3b5b999bb70036eb948f3513d9c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.",
                "category": "company",
                "datetime": 1783861500,
                "headline": "This Dividend ETF Choice Could Shape Your Income Strategy Through 2026"
              },
              {
                "id": 140876376,
                "url": "https://finnhub.io/api/news?id=a77b6a16e9d7a09cda7e708cd54b49ae5c2a7756f06852dfd9ceedcef2b6af02",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165090199/image_165090199.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Preview key market catalysts this week: big bank earnings, TSM, Netflix, CPI/PPI & Fed testimonyâplus SpaceX valuation insights.",
                "category": "company",
                "datetime": 1783838208,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 140872454,
                "url": "https://finnhub.io/api/news?id=68840e2adea7c97d4c19866e840047b39cd3d0fff9f8a3b7b0302d8e761f5c1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 10% dividend feels like a win because it solves the income problem with less capital. The arithmetic is seductive: $80,000 of annual income requires $800,000 at a 10% yield versus about $2.29 million at 3.5%. The catch shows up five, ten, and twenty years later. A fixed high yield may pay more today, but ... The Dividend Growth Plan That Leaves High-Yield Stocks Behind",
                "category": "company",
                "datetime": 1783788120,
                "headline": "The Dividend Growth Plan That Leaves High-Yield Stocks Behind"
              },
              {
                "id": 140871823,
                "url": "https://finnhub.io/api/news?id=1d9a73da5b10d2eaee3d12ac4534c19ad1480045183ba30d11bd68f651d9a30b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A stock screener sorted by current yield misses one of the most powerful income stories in the market. Microsoft (NASDAQ: MSFT) now pays $0.91 per quarter, up from $0.08 per quarter in 2005. Visa (NYSE: V) most recently paid $0.67 per quarter, and its annual dividend now totals $2.68. Those stocks do not look like ... Why Today’s Small Dividend Could Become Tomorrow’s Retirement Engine",
                "category": "company",
                "datetime": 1783783810,
                "headline": "Why Today’s Small Dividend Could Become Tomorrow’s Retirement Engine"
              },
              {
                "id": 140871834,
                "url": "https://finnhub.io/api/news?id=768cdf3917b80b9ef071b8c49e6ae5b85e81838d202d4edb8389c64b2806f2a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most retirement budgets start with the wrong question. The instinct is to ask, “What yield do I need so the nest egg covers the bills?” Higher yield shrinks the required capital, so the math seduces you toward 8%, 10%, or 12% strategies. Punch in the numbers, write down the smaller portfolio target, and breathe easier. ... The Retirement Budget Most People Build Is Backward",
                "category": "company",
                "datetime": 1783779303,
                "headline": "The Retirement Budget Most People Build Is Backward"
              },
              {
                "id": 140871111,
                "url": "https://finnhub.io/api/news?id=505b1cf88f9b6b817483c68f62ec48330c62c902fce5eef2592209a03ff95ff7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors panic when stocks turn red, but the losses that actually destroy wealth rarely show up on a bad trading day. Four household-name stocks reveal the quieter threats compounding beneath the surface.",
                "category": "company",
                "datetime": 1783772395,
                "headline": "Volatility Isn’t the Risk You Should Fear — These Are"
              },
              {
                "id": 140871585,
                "url": "https://finnhub.io/api/news?id=dd79a210b72ec6a7b7f17608596f44d1a1428a0189e4d47e2cb76e5041e2722f",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Wall Street Week Ahead: key earnings (JPM, BAC, GS), CPI/PPI, retail sales, IPOs & dividendsâget timely stock market updates and plan trades.",
                "category": "company",
                "datetime": 1783767600,
                "headline": "Banking Heavyweights To Kick Off Earnings Next Week"
              },
              {
                "id": 140869911,
                "url": "https://finnhub.io/api/news?id=bcd8f15ebb03e3568bc541bfac55c5852ab3cd576eba6ef9d27eee8464f7e20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "There are good reasons to invest in Lilly and to hold off.",
                "category": "company",
                "datetime": 1783760640,
                "headline": "Should You Buy Eli Lilly Stock? Here's My Honest Take."
              },
              {
                "id": 140866925,
                "url": "https://finnhub.io/api/news?id=75054f2723e01a96eefd1cf2df359e3272c96b78d7d250d2664015f34eed95c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The big banks dominate this week's reporting docket, though several notable companies from other sectors will also report, including Netflix, Johnson & Johnson, and others. With the outlook trending consistently higher, will companies be able to live up to expectations?",
                "category": "company",
                "datetime": 1783722720,
                "headline": "Q2 Earnings Season Arrives: Can Results Match Upbeat Expectations?"
              },
              {
                "id": 140866928,
                "url": "https://finnhub.io/api/news?id=1a2a33b52362ea52df721e569171903f9cd957133e2cbc01e06b2b1e08e3ae53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Illinois Appellate Court upheld a $45 million talc verdict against Johnson & Johnson. The decision confirms the original jury finding in a talc related case rather than reducing or overturning it. The ruling may influence expectations around ongoing talc litigation and future legal outcomes for the company. For investors following Johnson & Johnson (NYSE: JNJ), this legal outcome arrives while the stock trades at $256.98. The company has recorded a 7.8% return over the past 30 days and...",
                "category": "company",
                "datetime": 1783721593,
                "headline": "Johnson & Johnson (JNJ) Faces Fresh Talc Risk After $45 Million Verdict Stands"
              },
              {
                "id": 140866193,
                "url": "https://finnhub.io/api/news?id=3f2e5e14bc617aaa8b286e72852f6297e0309a66b1b3633b444202ad357502b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "DALLAS, July 10, 2026--Dean Omar Branham Shirley, LLP (DOBS), announced today that the Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who developed the deadly disease mesothelioma after decades of using Johnson & Johnson's Baby Powder. This product and other talc-based products have been found to be contaminated with asbestos.",
                "category": "company",
                "datetime": 1783715400,
                "headline": "Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue"
              },
              {
                "id": 140865308,
                "url": "https://finnhub.io/api/news?id=60c520a5ede9565f971f8e5a2dec91f4f809d6ae9f6eed0f06448f9b4ab0f03e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing $7,500 a month with dividends is a math problem before it is anything else. The number you need to invest depends almost entirely on the yield you chase, and each yield tier carries a different set of tradeoffs that reveal themselves only after you own the position for a decade. Across three broad approaches, ... Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead",
                "category": "company",
                "datetime": 1783710033,
                "headline": "Three Dividend Strategies That Can Produce $7,500 a Month and Which One Comes Out Ahead"
              },
              {
                "id": 140863713,
                "url": "https://finnhub.io/api/news?id=f1b2c2cebd6715831501571f2e0eaa6df6e4dbd5dd50cb7f5e5c18fd5cf66369",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1783701603,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140864246,
                "url": "https://finnhub.io/api/news?id=b1a157383c723c1c371bb7576a64e7316a8e0ae7ac0d7b038f20f7782821f25d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and some stretch past 18. The bill that comes with that lifespan is the part many owners never total, because the monthly receipts feel ... A Dividend Portfolio That Pays For Your Pets",
                "category": "company",
                "datetime": 1783701007,
                "headline": "A Dividend Portfolio That Pays For Your Pets"
              },
              {
                "id": 140864247,
                "url": "https://finnhub.io/api/news?id=c0977290006aa0018f206464a75fad8cbde03b207ba5408dea5f24fccec7059c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A single weak jobs report moved more money on Wall Street on Monday than any independent company's earnings ever could. That is what played out on Monday, July 6, 2026, and Jim Cramer thinks it handed patient investors a rare opening. The CNBC host argues that big investment funds sold off shares ...",
                "category": "company",
                "datetime": 1783700220,
                "headline": "Jim Cramer recommends buying these 5 stocks"
              },
              {
                "id": 140864232,
                "url": "https://finnhub.io/api/news?id=91a02918a5278124662a610b3899e8198d2c7971f595e01efcfbf99480df0d7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.",
                "category": "company",
                "datetime": 1783699478,
                "headline": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout"
              },
              {
                "id": 140862791,
                "url": "https://finnhub.io/api/news?id=9e7c969561b741d7d3e331613b4697e6f1fbaf278c8d61fdd3e72f5aecb85884",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.",
                "category": "company",
                "datetime": 1783697402,
                "headline": "Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner"
              },
              {
                "id": 140862919,
                "url": "https://finnhub.io/api/news?id=84e711be3858bf2df2c24f171da6d351fd3c2d23dd0caddd1da4b450befeb175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A dividend cut does not announce itself in advance, but the warning signs appear in the financials long before management steps up to the microphone. Morningstar's index strategists built a three-signal framework to spot the vulnerable payers before the bad news drops.",
                "category": "company",
                "datetime": 1783692520,
                "headline": "5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them."
              },
              {
                "id": 140864870,
                "url": "https://finnhub.io/api/news?id=7b37f6bd3e286a6ed53bebc2ef7cf932255b8912ecad61b51774df1929604ab6",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "B of A Securities  analyst Tim Anderson   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Neutral and raises the price target from $254 to $263.",
                "category": "company",
                "datetime": 1783692234,
                "headline": "B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $263"
              },
              {
                "id": 140864871,
                "url": "https://finnhub.io/api/news?id=0b230cf4ef13909094f0c290b905986804d9f285937fd22e25e8cdfb17957867",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783690507,
                "headline": "6 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140862907,
                "url": "https://finnhub.io/api/news?id=cb61a570439a0c8f576f20e29d2c5ae39d694ad9498a3421a02673d39ed5b2dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "U. S. stock futures traded little changed on Friday as investors paused after Thursday’s technology-led rally, shifting their attention toward next week’s corporate earnings reports and key inflation releases.",
                "category": "company",
                "datetime": 1783690270,
                "headline": "U.S. Futures Drift as Investors Await Earnings Season and Inflation Data: Dow Jones, S&P, Nasdaq"
              },
              {
                "id": 140862921,
                "url": "https://finnhub.io/api/news?id=1f52f873241b901f657ddaf086aba8d0e482b06569ce93acf95f3cf49f028cd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1783689306,
                "headline": "Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"
              },
              {
                "id": 140861579,
                "url": "https://finnhub.io/api/news?id=c62ba8099aee23158987217595678195e0459f312029919472cb27427facb95f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A long-term care policy does not just protect against a future care bill. It also creates a premium bill that may have to be paid for decades. A healthy 55-year-old buying meaningful inflation protection can face annual premiums in the low-to-mid thousands, and a 55-year-old couple can easily cross $5,000 combined. The planning question is: ... What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?",
                "category": "company",
                "datetime": 1783689157,
                "headline": "What Would It Take to Permanently Cover Long-Term Care Insurance Premiums?"
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140860612,
                "url": "https://finnhub.io/api/news?id=f9459f84a75170feabd63f20cc714d6a53208191cf6f97ca3ab4d9e39210c9f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "An investor who bought Microsoft (NASDAQ:MSFT) ten years ago paid closer to $50 per share than $45. Those shares now pay $3.64 per year in dividends, based on Microsoft’s current $0.91 quarterly payout. That is a yield on cost of roughly 7%, even though the stock’s current yield is about 1%. The starting yield helped, ... The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet",
                "category": "company",
                "datetime": 1783678805,
                "headline": "The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet"
              },
              {
                "id": 140856624,
                "url": "https://finnhub.io/api/news?id=d55803321975e4b10ca95fa10513a41f53df3cf2298ded23f8fbd88279d38d63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Thank you very much for attending! Question Answer Lots of reverb! Close zoom down and re-open the webinar Interesting issue of whether bio/medical, software, financials, small caps are just a rotation play versus an enduring trend, and whether AI is going to trend back up or just chop around Great Q. Might be yes and yes. Thx Cheers Bill, thank...",
                "category": "company",
                "datetime": 1783636387,
                "headline": "Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026"
              },
              {
                "id": 140854683,
                "url": "https://finnhub.io/api/news?id=f48afeae7fe86586e22a6c2aef80e8770dc29470f4a033873690b6b6dcd5c88a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Twelve thousand dollars a month sounds like a round number, but it carries weight. It works out to $144,000 a year, a little more than twice the U.S. per capita disposable personal income of $68,391 reported for the first quarter of 2026. Replacing that with portfolio income, rather than a paycheck, is a math problem ... How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?",
                "category": "company",
                "datetime": 1783623661,
                "headline": "How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?"
              },
              {
                "id": 140854599,
                "url": "https://finnhub.io/api/news?id=8a44172a2c0a8c1d20ba64981814906cb14203408f47f6475ad9da0de38e5b23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A sharp sector rotation has knocked down some of the market’s steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome. On the July 6 episode of Mad Money, Cramer framed the pullback this way: “These rotations create dislocations that seem to ... Jim Cramer: Buy the Dip on These 3 Stocks Now",
                "category": "company",
                "datetime": 1783622728,
                "headline": "Jim Cramer: Buy the Dip on These 3 Stocks Now"
              },
              {
                "id": 140852952,
                "url": "https://finnhub.io/api/news?id=0d784b8700baa9952e6e2725c6aabb3cd5fb07a43fc8a07af17486eee4f010a8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1783615204,
                "headline": "Top dow jones movers in Thursday's session"
              },
              {
                "id": 140853492,
                "url": "https://finnhub.io/api/news?id=a5af371c02f60aeaa2d1eae5f1e19dfac605beab7016a9f36c7f7c3abf491182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783613403,
                "headline": "Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140853417,
                "url": "https://finnhub.io/api/news?id=62b81d8d0d53fd3db3259bb6e645f20539ac41acef8be993c15f401fc48764d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Fundstrat’s Tom Lee returned to CNBC’s Morning Call Sheet on Thursday, July 9, alongside JonesTrading’s Mike O’Rourke and Vital Knowledge’s Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names. Lee argued: “AI is probably one of the most important structural stories in our lifetime.” ... Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally",
                "category": "company",
                "datetime": 1783612638,
                "headline": "Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140852127,
                "url": "https://finnhub.io/api/news?id=3dc0ae22f59ecc076a1a15b91bdc68fa65b5f68b674058d014aa38fddece5920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.",
                "category": "company",
                "datetime": 1783604422,
                "headline": "The Wide Chasm Priced Into Boston Scientific Stock"
              },
              {
                "id": 140854329,
                "url": "https://finnhub.io/api/news?id=f85d59ff5cf636e53f4a04b2a9899cbee55215709e026bf0dbff25839923e5cd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783604108,
                "headline": "9 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140850835,
                "url": "https://finnhub.io/api/news?id=9966738aa03e2c1d7bf64189594dd665e4ed1896a9b982f1abb0e878f0e60f2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The options market has priced a sizable range of outcomes for the surgical robotics leader, and if you hold the shares, you are already carrying that full exposure.",
                "category": "company",
                "datetime": 1783603762,
                "headline": "Just How Much Risk Is Built Into ISRG Stock?"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140850717,
                "url": "https://finnhub.io/api/news?id=5da71b8500b2edec56fc992ba44bfbf9dd1381fc160d75a661b1ff23ffbfe7d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The retirement income math often starts in the wrong place. A retiree who wants $60,000 a year might divide that figure by a portfolio yield and assume the highest yield is the most efficient path: about $1.71 million at 3.5%, $857,000 at 7%, or $500,000 at 12%. On day one, the 12% portfolio looks like ... Why the Best Retirement Paycheck May Start Smaller Than You Expect",
                "category": "company",
                "datetime": 1783602306,
                "headline": "Why the Best Retirement Paycheck May Start Smaller Than You Expect"
              },
              {
                "id": 140850838,
                "url": "https://finnhub.io/api/news?id=21dfd1aef1dc45094c955dfaeda9d3db8bbf9707517c7c6b649519abe0893c0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The math is simple. A $1 million portfolio generating $100,000 in annual income requires a blended yield of 10%. That is achievable today, but only by leaning hard into the aggressive end of the dividend spectrum. The question this article answers: what does that portfolio actually look like, and what happens when the highest yielder ... How a $1 Million Dividend Portfolio Can Generate $100,000 Annually",
                "category": "company",
                "datetime": 1783600234,
                "headline": "How a $1 Million Dividend Portfolio Can Generate $100,000 Annually"
              },
              {
                "id": 140850839,
                "url": "https://finnhub.io/api/news?id=4b0791faccaebf7adbccb171e2c837a1133100a353457857d7946eac73d54b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted the AI opportunities in neoclouds. Cramer was bullish on the stock and expects positive developments for the company, as he stated: You’re going to see some massive moves in real time for no reason whatsoever. Why do we care […]",
                "category": "company",
                "datetime": 1783599522,
                "headline": "Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”"
              },
              {
                "id": 140849942,
                "url": "https://finnhub.io/api/news?id=15fd3b700ed22c2dea115cbfc7c32543943c91b74084964d3e78b6e2fec65771",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $60,000 retirement paycheck sounds like a single target, but a portfolio can produce it in very different ways. A lower-yield portfolio demands more capital upfront but may give the income room to grow. A high-yield portfolio can shrink the capital requirement, but it usually asks the investor to accept more credit risk, distribution risk, ... The Retirement Portfolio That Pays You Without Demanding Constant Attention",
                "category": "company",
                "datetime": 1783597685,
                "headline": "The Retirement Portfolio That Pays You Without Demanding Constant Attention"
              },
              {
                "id": 140852128,
                "url": "https://finnhub.io/api/news?id=0d8d5355ebff870c994dea78b71564f062bb6a51ab8e04cbf1a91b3ad27b8cd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.",
                "category": "company",
                "datetime": 1783591200,
                "headline": "J&J wins FDA approval for dual-energy ablation catheter"
              },
              {
                "id": 140850500,
                "url": "https://finnhub.io/api/news?id=abd5251e75e6785b9c62af971b1d6f692745a5486eed4c6d763d18f9e5bce35f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248458314/image_2248458314.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker (SYK) buy rating after a rare Q1 miss from a temporary cyber disruption. Full-year guidance holds; demand strong.",
                "category": "company",
                "datetime": 1783588719,
                "headline": "Stryker: The Market Is Overreacting To One Disrupted Quarter"
              },
              {
                "id": 140848104,
                "url": "https://finnhub.io/api/news?id=3d852d8e32a79f75a1edee40b96b8722f59a65a19453849ad4e440bf4c3ebdfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A share of Johnson & Johnson (NYSE: JNJ) paid $0.25 per quarter in dividends in 1999. That same share pays $1.34 per quarter in 2026. The stock price has moved through plenty of cycles since then, but the income stream alone has more than quintupled without the investor doing anything except holding. That trajectory is ... The Case For Buying Smaller Dividends That Grow Faster",
                "category": "company",
                "datetime": 1783575229,
                "headline": "The Case For Buying Smaller Dividends That Grow Faster"
              },
              {
                "id": 140847016,
                "url": "https://finnhub.io/api/news?id=e615909c47c3bbca4e783286acbb04544f11c6c9106c7cb4982ae31045c50f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson recently received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an ablation catheter that can deliver both radiofrequency and pulsed field energy through a single device, integrated with the CARTO mapping ecosystem, with U.S. procedures set to begin following a phased commercial rollout this summer. This dual-energy, single-catheter approach could deepen Johnson & Johnson’s position in advanced electrophysiology by simplifying workflows for...",
                "category": "company",
                "datetime": 1783559555,
                "headline": "Dual-Energy EP Catheter Approval Could Be A Game Changer For Johnson & Johnson (JNJ)"
              },
              {
                "id": 140846321,
                "url": "https://finnhub.io/api/news?id=08f4b8e626af283395b79b6ad9d14df1b68dff29ce2866c801399bf9a1063791",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.",
                "category": "company",
                "datetime": 1783547104,
                "headline": "Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140843377,
                "url": "https://finnhub.io/api/news?id=0c81e90fd0177693e04c6f597f3094721aad21cf484f4f5e2f07a9365658f254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you hold shares in this surgical robotics leader, you are already carrying a sizable two-sided risk, whether you trade options or not.",
                "category": "company",
                "datetime": 1783528899,
                "headline": "Just How Wide Is The Path Ahead For Intuitive Surgical Stock?"
              },
              {
                "id": 140853485,
                "url": "https://finnhub.io/api/news?id=7b86bbff6fb3fc6485d7790cc61a4572282dd3e8f99f0b1c923747f3f413dee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.",
                "category": "company",
                "datetime": 1783528500,
                "headline": "The Market Just Got Shaken—These 3 ETFs May Come Out Stronger"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140843952,
                "url": "https://finnhub.io/api/news?id=3018272f12e8143d30f18b292420d5c4acbe0d3d8e83b86b9588d1bebf4876ac",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253448108/image_2253448108.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Legend Biotech Corporation outlook: Carvykti drives upside in multiple myeloma, plus LB2501 optionality. Click for this updated look at LEGN stock.",
                "category": "company",
                "datetime": 1783521966,
                "headline": "A New Look At Legend Biotech: Plenty Of Upside For Carvykti"
              },
              {
                "id": 140853129,
                "url": "https://finnhub.io/api/news?id=986b3d1d89892df81985808d7bbb42421da3007c0a3099065e808f565579d207",
                "image": "https://image.cnbcfm.com/api/v1/image/108332264-17835331231783533120-47039073227-1080pnbcnews.jpg?v=1783533122&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Victoria Greene, G Squared Private Wealth, joins 'The Exchange' to discuss how investors should position, which type of stocks to favor and much more.",
                "category": "company",
                "datetime": 1783520303,
                "headline": "Favor Nvidia and Apple now as they are capex light, says G Squared's Victoria Greene"
              },
              {
                "id": 140853203,
                "url": "https://finnhub.io/api/news?id=cd79bc33512abc2a735e65d0de5a0445a51d2b2210e7df8dae0a272af1adbec7",
                "image": "https://image.cnbcfm.com/api/v1/image/108332252-17835317791783531776-47038724915-1080pnbcnews.jpg?v=1783531778&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the dealmaking cycle and much more.",
                "category": "company",
                "datetime": 1783517749,
                "headline": "Dealmaking in biotech sector has brought an extreme technical breakout, says UBS' Michael Yee"
              },
              {
                "id": 140842821,
                "url": "https://finnhub.io/api/news?id=121f9254926761f799768afd3501c8a7b8a784f3ac016fea40973077011d85b5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2284613261/image_2284613261.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, timeline, & upside. Click for a CMPS stock update.",
                "category": "company",
                "datetime": 1783517032,
                "headline": "Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission"
              },
              {
                "id": 140846016,
                "url": "https://finnhub.io/api/news?id=e31a1ac212d068a0cdeb4424eac924a6439cf98b06cf1eab8753dbc3164925c8",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Overweight and raises the price target from $283 to $284.",
                "category": "company",
                "datetime": 1783515518,
                "headline": "Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $284"
              },
              {
                "id": 140840466,
                "url": "https://finnhub.io/api/news?id=ba0edb8678292f7637ad16b2934dae337c3ef3760794d05a61f7e4f34e6b582c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.",
                "category": "company",
                "datetime": 1783513980,
                "headline": "3 Cancer Stocks to Watch as Oncology Innovation Accelerates"
              },
              {
                "id": 140839590,
                "url": "https://finnhub.io/api/news?id=0b3f1e61efb1fb0820fb42c400f359822f8c4ff3603783802b2e65fb1846e0a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "IRVINE, Calif., July 08, 2026--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform",
                "category": "company",
                "datetime": 1783511100,
                "headline": "Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform"
              },
              {
                "id": 140846017,
                "url": "https://finnhub.io/api/news?id=22d5ef0d95b8c47e4b8dcb1c4c7da0d6de852a0852d139fc9de9542768ac57fb",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Johnson &amp; Johnson (NYSE:JNJ) with a Buy and raises the price target from $285 to $298.",
                "category": "company",
                "datetime": 1783510883,
                "headline": "Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $298"
              },
              {
                "id": 140839591,
                "url": "https://finnhub.io/api/news?id=de549ecb2af71266d774d1161f4e028d20e3fc0e0b1f3120348e1e8ee1e12921",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average American household spent $78,535 in 2024, according to the latest Bureau of Labor Statistics Consumer Expenditure Survey. Round that to $80,000, and you have a useful starting point for the retirement paycheck many households may need to replace. Gross salary can overstate the target because it includes payroll taxes, retirement contributions, and expenses ... How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing",
                "category": "company",
                "datetime": 1783509106,
                "headline": "How A 2.5% Yield Can Turn Into A Retirement Paycheck That Keeps Growing"
              },
              {
                "id": 140839535,
                "url": "https://finnhub.io/api/news?id=7726ae2cdedb1c33a615b6638f4e25f37fdd8dc901db4aa554334e0691a5e29e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Turning $500,000 into $100,000 of annual income requires a 20% yield, and no durable, diversified income portfolio should be built around that assumption. Anyone quoting a number that high is usually taking on extreme risk, relying on leverage, or handing back some of your own capital. The dividend-growth formula solves a different equation. It accepts ... The Dividend Growth Formula That Turns $500,000 Into a Six-Figure Income Stream",
                "category": "company",
                "datetime": 1783505506,
                "headline": "The Dividend Growth Formula That Turns $500,000 Into a Six-Figure Income Stream"
              },
              {
                "id": 140839793,
                "url": "https://finnhub.io/api/news?id=303ee684ee433beba364a488812c644cbdf27564c78a5b59a237e3643f317e29",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172700619/image_2172700619.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker stock looks undervalued with a 13% discount to fair value, a strong EPS growth outlook, and dividend potential. Click for more on SYK stock.",
                "category": "company",
                "datetime": 1783497600,
                "headline": "Stryker: Medtech On Sale, Benefiting From Industry Growth"
              },
              {
                "id": 140846018,
                "url": "https://finnhub.io/api/news?id=330e695f6a29c90eab3bbf4a2ab26fe5511bb4c8042095c2e87876f6200ea29d",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "The Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single",
                "category": "company",
                "datetime": 1783496808,
                "headline": "Johnson & Johnson Receives FDA Approval For Its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Platform"
              },
              {
                "id": 140839188,
                "url": "https://finnhub.io/api/news?id=8d92f502e9ae3cee37efc06a64a391481098d0484fdfdf8c42da0d4610d75f7d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266159674/image_2266159674.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson has the momentum on its side and it is possible for the stock to increase further. Find out why JNJ stock is a hold.",
                "category": "company",
                "datetime": 1783493220,
                "headline": "Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 245,
            "discarded_article_count": 224
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 8813293.333333334,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8147790,
              "avg_vol_20": 9348375,
              "avg_vol_30": 8813293.333333334,
              "range_pct_10": 0.09396345173364462,
              "range_pct_20": 0.1685153456910478,
              "range_pct_30": 0.17494573688024517,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9244886890560774,
              "dist_to_20d_high": 0.07649475101119954,
              "down_shrink_days": 4,
              "breakout_level_20d": 269.42999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5371005513439004
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.613053508035789,
              "turnoverUsdM": 2018.3408341165,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 235.8164,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.2,
            "take_profit_price": 261.261,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.226107016071578,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 6.5018,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.61
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -22.84
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0873
    },
    "kdj": {
      "d": 30.93,
      "j": 2.79,
      "k": 21.55,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 24.56
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 6943650,
      "recentSlope": -2062335,
      "previousSlope": 6332850
    },
    "rsi": 41.54,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 264.4554,
      "position": "SAR喺價上",
      "distancePct": 6.28,
      "previousTrend": "下降"
    },
    "ma50": 239.143,
    "macd": {
      "macd": 3.7410485970696072,
      "trend": "中性偏多",
      "signal": 5.514378710678324,
      "histogram": -1.7733301136087167
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 252.0049,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.92,
      "score": 4,
      "avgVolume": 8804468,
      "currentVolume": 8111650
    },
    "derived": {
      "ma20": 252.8465,
      "ma50": 239.143,
      "prevClose": 253.04,
      "avgVolume10": 8278585,
      "avgVolume20": 8804468,
      "changePercent": -1.67,
      "avgVolumeForScore": 8804468
    },
    "ma_cross": {
      "ma20": 252.8465,
      "ma50": 239.143,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 251.825,
      "prevMa50": 238.659,
      "spreadPct": 5.73,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 235.5241,
      "upper": 270.1689,
      "position": "中間"
    },
    "rsi_short": 31.27,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.92
    }
  }
}

Raw metrics JSON

{
  "close": 248.82,
  "volume": 8111650,
  "changePercent": -1.67
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.

US.JNJ · Johnson & Johnson

避免

Score and price trend

Summary

Rolling setup rating

Has the score quality changed?

Signals

Full calculation detail

Market inputs

Metrics snapshot

110-point main rating

基本面 — 4.4/5 · 優秀

Sub-items

資金流 — 6.8/20 · 較差

Sub-items

institutional

details

warning

市場環境 — 7.2/15 · 較差

Sub-items

vix

details

trend

details

qqq

spy

催化劑 — 2/20 · 較差

Sub-items

catalyst

details

風險管理 — 7/10 · 良好

Sub-items

position

details

stopLevels

strength_details

diversification

details

技術信號 — 16.8/30 · 較差

Sub-items

vcpPayload

vcp_metrics

情緒分析 — 4/10 · 較差

Sub-items

sentiment

details

sentimentData

Dimension contribution

5D momentum v2 breakdown

Risk management

position

details

stopLevels

strength_details

diversification

details

Calculation audit log

Technical indicators

Raw calculation JSON

Raw metrics JSON